ID	Source	PAID	Summary	Phenotype	Genotype	Recommendation	Avoid	Alternate	Dosing	Gene	Drug	GeneID	DrugID
1	RNPGx	PA166202501	"Testing for the main CYP2C19 deficiency alleles before instituting clopidogrel treatment is recommended (a test is essential for coronary angioplasty with stenting and based on the current state of knowledge this test is potentially useful in the other indications). For patients carrying at least one deficiency allele, the RNPGx recommends using an alternative treatment that is not a CYP2C19 substrate (eg. prasugrel, ticagrelor)."	*2; *3	*2; *3	"In patients carrying at least one deleterious CYP2C19*2 or CYP2C19*3 allele who have a high risk of thromboembolic recurrence, an alternative antiaggregant that is not a CYP2C19 substrate (prasugrel,ticagrelor, acetylsalicylic acid. . .) is preferable.\nBased on current knowledge, it is not recommended to increase the clopidogrel dose in patients carrying the CYP2C19*2 or *3 allele."	1	1	1	CYP2C19	clopidogrel	4349	842
2	AusNZ	PA166257241	An alternative antifungal agent should be considered instead of voriconazole in patients who are known to be CYP2C19 ultrarapid metabolizers. CYP2C19 genotyping and use of an alternative antifungal agent is also recommended in patients with subtherapeutic voriconazole serum concentrations despite two dose adjustments.	Ultrarapid Metabolizer		"1. Consider switching to alternative antifungal agent and CYP2C19 genotype testing if voriconazole serum concentrations remain subtherapeutic despite two appropriate dose adjustments (Moderate recommendation, Level III evidence).\n2. Consider antifungal agents other than voriconazole if patient is a known CYP2C19 ultrarapid metaboliser (Strong recommendation, Level III evidence)."	1	1	1	CYP2C19	voriconazole	4349	3473
3	RNPGx	PA166202561	"Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause."	*1/*5; rs4149056 TC	*1/*5; rs4149056 TC	"(i) Against prescribing simvastatin at 80 mg/d the first year of treatment (and more generally any maximum dose statin if there is a doubt about tolerance); (ii) For simvastatin, to reduce the dose to 40 mg/d maximum in heterozygous patients (SLCO1B1*1/*5). Under these conditions, in the event of treatment failure or toxicity, an alternative treatment should be envisaged; (iii) In all situations for patients carriers of the rs4149056 allele, use of the minimal statin dose, close monitoring of creatinine phosphokinase levels, and avoiding combining the statin with OATP1B1 inhibitors (susceptible of increasing the exposure to statins)."	1	1	1	SLCO1B1	hmg coa reductase inhibitors	19487	1571
4	RNPGx	PA166202561	"Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause."	*5/*5; rs4149056 CC	*5/*5; rs4149056 CC	"(i) Against prescribing simvastatin at 80 mg/d the first year of treatment (and more generally any maximum dose statin if there is a doubt about tolerance); (ii) For simvastatin, to reduce the dose to 20 mg/d maximum in homozygous patients (SLCO1B1*5/*5). Under these conditions, in the event of treatment failure or toxicity, an alternative treatment should be envisaged; (iii) In all situations for patients carriers of the rs4149056 allele, use of the minimal statin dose, close monitoring of creatinine phosphokinase levels, and avoiding combining the statin with OATP1B1 inhibitors (susceptible of increasing the exposure to statins)."	1	1	1	SLCO1B1	hmg coa reductase inhibitors	19487	1571
5	RNPGx	PA166202561	"Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause."	*1/*5; rs4149056 TC	*1/*5; rs4149056 TC	"(i) Against prescribing simvastatin at 80 mg/d the first year of treatment (and more generally any maximum dose statin if there is a doubt about tolerance); (ii) For simvastatin, to reduce the dose to 40 mg/d maximum in heterozygous patients (SLCO1B1*1/*5). Under these conditions, in the event of treatment failure or toxicity, an alternative treatment should be envisaged; (iii) In all situations for patients carriers of the rs4149056 allele, use of the minimal statin dose, close monitoring of creatinine phosphokinase levels, and avoiding combining the statin with OATP1B1 inhibitors (susceptible of increasing the exposure to statins)."	1	1	1	SLCO1B1	simvastatin	19487	2979
6	RNPGx	PA166202561	"Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause."	*5/*5; rs4149056 CC	*5/*5; rs4149056 CC	"(i) Against prescribing simvastatin at 80 mg/d the first year of treatment (and more generally any maximum dose statin if there is a doubt about tolerance); (ii) For simvastatin, to reduce the dose to 20 mg/d maximum in homozygous patients (SLCO1B1*5/*5). Under these conditions, in the event of treatment failure or toxicity, an alternative treatment should be envisaged; (iii) In all situations for patients carriers of the rs4149056 allele, use of the minimal statin dose, close monitoring of creatinine phosphokinase levels, and avoiding combining the statin with OATP1B1 inhibitors (susceptible of increasing the exposure to statins)."	1	1	1	SLCO1B1	simvastatin	19487	2979
7	CPIC	PA166122686	"The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction."	Poor Metabolizer		"Activity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.\nActivity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens."	1	1	1	DPYD	fluorouracil	5039	1390
8	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Poor Function		"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy)."	0	1	1	ABCG2	rosuvastatin	83	2890
9	CPIC	PA166105002	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers."	Ultrarapid Metabolizer		"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	desipramine	4352	1005
10	CPIC	PA166105002	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers."	Poor Metabolizer		"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	desipramine	4352	1005
11	DPWG	PA166182844	"Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms."	SLCO1B1 521 TC	rs4149056 TC	"1. Choose an alternative.\nConsider any additional risk factors for statin-induced myopathy.\nAtorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patients with additional risk factors for statin-induced myopathy.\nRosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.\nFluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.\n2. If an alternative is not an option:\n1. Avoid simvastatin doses exceeding 40mg/day.\n2. Advise the patient to contact their doctor in the event of muscle symptoms."	1	1	1	SLCO1B1	simvastatin	19487	2979
12	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	doxepin	4352	1126
13	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	doxepin	4352	1126
14	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	doxepin	4349	1126
15	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Rapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	doxepin	4349	1126
16	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nFor tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	doxepin	4349	1126
17	CPIC	PA166127638	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19."	Poor Metabolizer		Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.	0	1	1	CYP2C19	citalopram	4349	819
18	CPIC	PA166127638	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19."	Poor Metabolizer		Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.	0	1	1	CYP2C19	escitalopram	4349	1263
19	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	trimipramine	4352	3339
20	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	trimipramine	4352	3339
21	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	trimipramine	4349	3339
22	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Rapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	trimipramine	4349	3339
23	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nFor tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	trimipramine	4349	3339
24	DPWG	PA166104970	"The Pharmacogenetics Working Group Guideline for codeine includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer, higher or lower doses and additional risk factors are taken into consideration."	Ultrarapid Metabolizer		"DOSES HIGHER THAN 20 mg every 6 hours for adults and 10 mg every 6 hours for children aged 12 years or older AND/OR ADDITIONAL RISK FACTORS, such as co-medication with CYP3A4 inhibitors and/or reduced kidney function:\nCodeine is contra-indicated.\nif possible, select an alternative\n- For PAIN: do not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.\n- For COUGH: noscapine is not metabolised by CYP2D6.\n \nDOSES LOWER THAN OR EQUAL TO 20 mg every 6 hours for adults and 10 mg every 6 hours for children aged 12 years or older AND NO ADDITIONAL RISK FACTORS, such as co-medication with CYP3A4 inhibitors and/or reduced kidney function:\nNo action required."	0	1	1	CYP2D6	codeine	4352	854
25	DPWG	PA166104970	"The Pharmacogenetics Working Group Guideline for codeine includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer, higher or lower doses and additional risk factors are taken into consideration."	Intermediate Metabolizer		"For COUGH:\n1. No action required.\n \nFor PAIN:\nIt is not possible to offer adequately substantiated advice for dose adjustment based on the limited available literature for this phenotype.\n1. Be alert to a reduced effectiveness.\n2. In the case of inadequate effectiveness: 1. Try a dose increase., 2. If this does not work: choose an alternative.\nDo not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.\n3. If no alternative is selected: advise the patient to report inadequate analgesia."	0	1	1	CYP2D6	codeine	4352	854
26	DPWG	PA166104970	"The Pharmacogenetics Working Group Guideline for codeine includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer, higher or lower doses and additional risk factors are taken into consideration."	Poor Metabolizer		"For COUGH:\n1. No action required.\n \nFor PAIN:\nIt is not possible to offer adequately substantiated advice for dose adjustment based on the limited available literature for this phenotype.\n1. Choose an alternative.\nDo not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.\n2. If an alternative is not an option: advise the patient to report inadequate analgesia."	0	1	1	CYP2D6	codeine	4352	854
27	DPWG	PA166104944	"Choose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 0	AS 0	"Avoid tegafur\nFluorouracil and capecitabine are not suitable alternatives, as these are also metabolised by DPD.\n- If it is not possible to avoid tegafur: start with a very low dose and adjust the initial dose based on toxicity and efficacy. A substantiated recommendation for dose reduction cannot be made based on the literature."	1	1	1	DPYD	tegafur	5039	3158
28	DPWG	PA166104944	"Choose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 1	AS 1	"Avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD.  It is not possible to offer substantiated advice for dose reduction based on the literature."	1	1	1	DPYD	tegafur	5039	3158
29	DPWG	PA166104944	"Choose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 1.5	AS 1.5	"Avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy.  Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature."	1	1	1	DPYD	tegafur	5039	3158
30	DPWG	PA166104952	Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	Poor Metabolizer		"Choose an alternative or start with 10% of the standard dose.\nAny adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.\nIf the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur"	0	1	1	TPMT	mercaptopurine	22019	1994
31	DPWG	PA166104960	Select an alternative drug or reduce the initial dose of thioguanine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	Poor Metabolizer		"1. Choose an alternative or start with 6-7% of the standard dose.  Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.\n2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) develop."	0	1	1	TPMT	thioguanine	22019	3233
32	CPIC	PA166127639	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.	Poor Metabolizer		Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.	0	1	1	CYP2C19	sertraline	4349	2963
33	DPWG	PA166104988	The recommendation for CYP2D6 poor metabolizers is to use 60% of the standard dose of haloperidol and for CYP2D6 ultrarapid metabolizers to use 1.5 times the standard dose or to choose an alternative to haloperidol.	Ultrarapid Metabolizer		"Use 1.5 times the standard dose or choose an alternative.\nAntipsychotics that are not metabolised by CYP2D6 - or to a much lesser extent - include, for example, flupentixol, penfluridol, quetiapine, olanzapine or clozapine."	0	1	1	CYP2D6	haloperidol	4352	1542
34	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Poor Metabolizer		"For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy."	0	1	1	TPMT	mercaptopurine	22019	1994
35	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Poor Metabolizer		"For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy."	0	1	1	NUDT15	mercaptopurine	13756	1994
36	DPWG	PA166104939	"An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 0	AS 0	"1. Avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolised by DPD.\n2. If if is not possible to avoid fluorouracil and capecitabine: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped)."	1	1	1	DPYD	fluorouracil	5039	1390
37	DPWG	PA166104939	"An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 0	AS 0	"1. Avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolised by DPD.\n2. If if is not possible to avoid fluorouracil and capecitabine: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped)."	1	1	1	DPYD	capecitabine	5039	655
38	DPWG	PA166104939	"An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 1	AS 1	"Start with 50% of the standard dose or avoid fluorouracil and capecitabine. Adjustment of the subsequent dose should be guided by toxicity and effectiveness. However, in one study involving 17 patients with gene activity 1, the average dose after titration was 57% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD."	1	1	1	DPYD	fluorouracil	5039	1390
39	DPWG	PA166104939	"An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 1	AS 1	"Start with 50% of the standard dose or avoid fluorouracil and capecitabine. Adjustment of the subsequent dose should be guided by toxicity and effectiveness. However, in one study involving 17 patients with gene activity 1, the average dose after titration was 57% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD."	1	1	1	DPYD	capecitabine	5039	655
40	DPWG	PA166104939	"An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 1.5	AS 1.5	"Start with 50% of the standard dose or avoid fluorouracil and capecitabine. After starting treatment, the dose should be adjusted based on toxicity and effectiveness. In a study involving 17 patients with genotype 1/2846T, the average dose after titration was 64% of the standard dose. For 51 patients with genotype 1/1236A, the average dose after titration was 74% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD."	1	1	1	DPYD	fluorouracil	5039	1390
41	DPWG	PA166104939	"An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 1.5	AS 1.5	"Start with 50% of the standard dose or avoid fluorouracil and capecitabine. After starting treatment, the dose should be adjusted based on toxicity and effectiveness. In a study involving 17 patients with genotype 1/2846T, the average dose after titration was 64% of the standard dose. For 51 patients with genotype 1/1236A, the average dose after titration was 74% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD."	1	1	1	DPYD	capecitabine	5039	655
42	DPWG	PA166265421	Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers.	Poor Metabolizer		Indication DEPRESSION: choose an alternative.\nAripiprazole appears to be less dependent on CYP3A4 for metabolism. Olanzapine is not metabolised by CYP3A4.\nOTHER INDICATIONS: use 30% of the standard dose.	0	1	1	CYP3A4	quetiapine	4366	2788
43	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Poor Function		"Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day."	0	1	1	SLCO1B1	fluvastatin	19487	1406
44	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Intermediate Metabolizer		"Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy)."	0	1	1	CYP2C9	fluvastatin	4351	1406
45	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Poor Metabolizer		"Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy)."	0	1	1	CYP2C9	fluvastatin	4351	1406
46	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	imipramine	4352	1648
47	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	imipramine	4352	1648
48	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	imipramine	4349	1648
49	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Rapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	imipramine	4349	1648
50	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nFor tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	imipramine	4349	1648
51	CPIC	PA166176068	"The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy."	Poor Metabolizer	AS 0	"Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:26211827, 24881463] and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence [Article:23213055]. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy [Articles:27226358, 21768473]."	0	1	1	CYP2D6	tamoxifen	4352	3137
52	CPIC	PA166262241	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Decreased Function		"Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day."	0	1	1	SLCO1B1	lovastatin	19487	1894
53	CPIC	PA166262241	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Possible Decreased Function		"Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day."	0	1	1	SLCO1B1	lovastatin	19487	1894
54	DPWG	PA166265141	Individuals with the HLA-B*58:01 allele should be given an alternative drug or undergo induction of allopurinol tolerance.	HLA-B*58:01 positive		"1. Choose an alternative, such as febuxostat 2. Another option is to induce allopurinol tolerance first: To induce allopurinol tolerance, the allopurinol dose is increased every 3 days until a dose of 100 mg/day has been achieved on Day 28. The consecutive daily doses in the induction protocol are 50 µg, 100 µg, 200 µg, 500 µg, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg and 100 mg."	0	1	1	HLA-B	allopurinol	8015	127
55	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	amitriptyline	4352	195
56	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	amitriptyline	4352	195
57	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	amitriptyline	4349	195
58	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Rapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	amitriptyline	4349	195
59	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nFor tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	amitriptyline	4349	195
60	CPIC	PA166127637	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.	Poor Metabolizers		Consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6.	0	1	1	CYP2D6	fluvoxamine	4352	1407
61	CPIC	PA166105005	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Decreased Function		"Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day."	0	1	1	SLCO1B1	simvastatin	19487	2979
62	CPIC	PA166105005	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Possible Decreased Function		"Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day."	0	1	1	SLCO1B1	simvastatin	19487	2979
63	DPWG	PA166104968	"For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine."	Ultrarapid Metabolizer		"Recommendation:\n1. be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O-desmethylvenlafaxine\n2. if necessary, increase the dose to 150% of the standard dose\n3. if dose adjustment based on therapeutic drug monitoring is not possible, an alternative should be selected. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline."	0	1	1	CYP2D6	venlafaxine	4352	3423
64	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Poor Metabolizer		"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib and 5 days for ibuprofen, flurbiprofen and lornoxicam after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo."	0	1	1	CYP2C9	celecoxib	4351	736
65	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Poor Metabolizer		"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib and 5 days for ibuprofen, flurbiprofen and lornoxicam after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo."	0	1	1	CYP2C9	flurbiprofen	4351	1400
66	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Poor Metabolizer		"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib and 5 days for ibuprofen, flurbiprofen and lornoxicam after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo."	0	1	1	CYP2C9	ibuprofen	4351	1621
67	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Poor Metabolizer		"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib and 5 days for ibuprofen, flurbiprofen and lornoxicam after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo."	0	1	1	CYP2C9	lornoxicam	4351	1890
68	DPWG	PA166104959	"Be alert to a reduced efficacy of tramadol in CYP2D6 intermediate or poor metabolizers. If tramadol is not effective in these patients, try a dose increase or select an alternative to tramadol (not codeine) and be alert for symptoms of insufficient pain relief. For CYP2D6 ultrarapid metabolizers, use an alternative to tramadol (not codeine) or use 40% of the standard dose and be alert to side effects."	Ultrarapid Metabolizer		"As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.\n1. Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.\n2. If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention)."	0	1	1	CYP2D6	tramadol	4352	3302
69	DPWG	PA166182823	"The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CYP3A inducers."	Intermediate Metabolizer		"- Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR: Eliglustat is contra-indicated.\n1. Choose an alternative if possible.\nStrong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.\n \n- Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):\n1. Use a dose of 84mg eliglustat 1x daily.\n \n- Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):\n1. Consider a dose of 84mg eliglustat 1x daily.\n2. Be alert to side effects.\n \n- Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):\n1. Choose an alternative if possible.\n2. If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.\n \n- Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):\n1. Choose an alternative.\n2. If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.\n \n- Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.\n1. Choose an alternative if possible.\n \n- NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:\n1. Use the standard dose of 84mg 2x daily."	0	1	1	CYP2D6	eliglustat	4352	1202
70	DPWG	PA166182823	"The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CYP3A inducers."	Poor Metabolizer		"- Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir): Eliglustat is contra-indicated.\n1. Choose an alternative if possible.\n \n- Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine): Eliglustat is not recommended.\n1. Choose an alternative if possible.\n \n- Co-medication with a WEAK CYP3A INHIBITOR (for example amlopidine, cilostazole, fluvoxamine, goldenseal, isoniazide, ranitidine, ranolazine):\n1. Choose an alternative for the weak CYP3A inhibitor if possible.\n2. If an alternative is not an option: Use a dose of 84mg eliglustat 1x daily and be alert to side effects.\n \n- Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.\n1. Choose an alternative if possible.\n \n- NO co-medication with a CYP3A inhibitor or strong CYP3A inducer:\n1. Use a dose of 84mg 1x daily."	0	1	1	CYP2D6	eliglustat	4352	1202
71	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Poor Metabolizer		"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment."	0	1	1	TPMT	azathioprine	22019	432
72	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Poor Metabolizer		"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment."	0	1	1	NUDT15	azathioprine	13756	432
73	DPWG	PA166104934	Select an alternative drug or reduce the initial dose of azathioprine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	Poor Metabolizer		"Choose an alternative or start with 10% of the standard dose.\nAny adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.\nIf the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur."	0	1	1	TPMT	azathioprine	22019	432
74	CPIC	PA166109594	"The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction."	Poor Metabolizer		"Activity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.\nActivity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens."	1	1	1	DPYD	capecitabine	5039	655
75	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Poor Metabolizer		"Start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy."	0	1	1	TPMT	thioguanine	22019	3233
76	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Poor Metabolizer		"Reduce doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy."	0	1	1	NUDT15	thioguanine	13756	3233
77	DPWG	PA166104943	The Dutch Pharmacogenetics Working Group Guideline for risperidone recommends decreasing the dose for CYP2D6 poor metabolizers and using an alternative drug or titrate the dose according to the maximum dose for the active metabolite for CYP2D6 ultrarapid metabolizers.	Ultrarapid Metabolizer		Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).	0	1	1	CYP2D6	risperidone	4352	2871
78	CPIC	PA166104998	"The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers."	Ultrarapid Metabolizer		"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	nortriptyline	4352	2240
79	CPIC	PA166104998	"The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers."	Poor Metabolizer		"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	nortriptyline	4352	2240
80	DPWG	PA166104966	"For CYP2D6 poor and intermediate metabolizers, consider an alternative medication or a dose increase. For intermediate metabolizers, avoid concomitant CYP2D6 inhibitor use."	Intermediate Metabolizer		1. Select an alternative or measure the endoxifen concentration and increase the dose if necessary by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.\n2. If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine	1	1	1	CYP2D6	tamoxifen	4352	3137
81	DPWG	PA166104966	"For CYP2D6 poor and intermediate metabolizers, consider an alternative medication or a dose increase. For intermediate metabolizers, avoid concomitant CYP2D6 inhibitor use."	Poor Metabolizer		Select an alternative or increase the dose to 40 mg/day and monitor the endoxifen concentration. Studies have demonstrated that PM can achieve an adequate endoxifen concentration when the dose is increased to 40-60 mg/day. Aromatase inhibitors are a possible alternative for post-menopausal women.	0	1	1	CYP2D6	tamoxifen	4352	3137
82	CPIC	PA166192301	"The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2)."	0	1	1	CYP2C9	meloxicam	4351	1977
83	CPIC	PA166262261	Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.	Decreased Function		"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg.  If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)."	0	1	1	SLCO1B1	pitavastatin	19487	2639
84	CPIC	PA166262261	Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.	Possible Decreased Function		"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg.  If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)."	0	1	1	SLCO1B1	pitavastatin	19487	2639
85	CPIC	PA166262261	Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.	Poor Function		"Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1mg needed for desired efficacy, consider an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(3)."	0	1	1	SLCO1B1	pitavastatin	19487	2639
86	CPIC	PA166127636	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response."	Poor Metabolizers		"Select alternative drug not predominantly metabolized by CYP2D6 or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response."	0	1	1	CYP2D6	paroxetine	4352	2520
87	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	clomipramine	4352	838
88	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\nIf a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2D6	clomipramine	4352	838
89	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Ultrarapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	clomipramine	4349	838
90	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Rapid Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	clomipramine	4349	838
91	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Poor Metabolizer		"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\nFor tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments."	1	1	1	CYP2C19	clomipramine	4349	838
92	DPWG	PA166104963	"An alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 0	AS 0	"1. Avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolised by DPD.\n2. If if is not possible to avoid fluorouracil and capecitabine: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped)."	1	1	1	DPYD	capecitabine	5039	655
93	DPWG	PA166104963	"An alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 1	AS 1	"Start with 50% of the standard dose or avoid fluorouracil and capecitabine. Adjustment of the subsequent dose should be guided by toxicity and effectiveness. However, in one study involving 17 patients with gene activity 1, the average dose after titration was 57% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD."	1	1	1	DPYD	capecitabine	5039	655
94	DPWG	PA166104963	"An alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 1.5	AS 1.5	"Start with 50% of the standard dose or avoid fluorouracil and capecitabine. After starting treatment, the dose should be adjusted based on toxicity and effectiveness. In a study involving 17 patients with genotype 1/2846T, the average dose after titration was 64% of the standard dose. For 51 patients with genotype 1/1236A, the average dose after titration was 74% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD."	1	1	1	DPYD	capecitabine	5039	655
95	DPWG	PA166104956	"Avoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers."	Intermediate Metabolizer		"PERCUTANEOUS CORONARY INTERVENTION, STROKE or TIA: choose an alternative or double the dose to 150 mg/day (600 mg loading dose). Prasugrel, ticagrelor and acetylsalicylic acid/dipyridamole are not metabolised by CYP2C19 (or to a lesser extent).\nOTHER INDICATIONS: no action required"	0	1	1	CYP2C19	clopidogrel	4349	842
96	CPIC	PA166262281	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Poor Function		"Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40mg."	0	1	1	SLCO1B1	pravastatin	19487	2688
97	DPWG	PA166104995	"For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, use smaller steps in dose titration and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug."	Ultrarapid Metabolizer		1. use the maximum dose for the relevant indication as a target dose. 2. if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative. Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.	0	1	1	CYP2D6	metoprolol	4352	2052
98	RNPGx	PA166202521	"Testing for TPMT genotype and phenotype is recommended for patients who are receiving azathioprine as an immunosuppressant. A dose reduction should be considered for patients with intermediate TPMT activity, while a greater dose reduction or selection of an alternate drug should be considered for patients with low TPMT activity."	Normal Metabolizer; Indeterminate		Dose adjustment: Standard dose. Initial dose: Azathioprine 2.0-2.5 mg/kg/day.	1	0	1	TPMT	azathioprine	22019	432
99	CPIC	PA166104949	"The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823."	*3	*3	"For non-African ancestry, if the CYP4F2*3 (i.e., rs2108622, c.1297A, p.433Met) allele is also detected, increase the dose by 5-10%."	1	0	1	CYP4F2	warfarin	4376	3480
100	CPIC	PA166104949	"The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823."	rs9923231 CC	rs9923231 CC	A increased dose of warfarin. Calculate warfarin dose using a validated pharmacogenetic algorithm.	1	0	1	VKORC1	warfarin	23312	3480
101	CPIC	PA166104949	"The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823."	rs9923231 CT; rs9923231 TT	rs9923231 CT; rs9923231 TT	A decreased dose of warfarin. Calculate warfarin dose using a validated pharmacogenetic algorithm.	1	0	1	VKORC1	warfarin	23312	3480
102	CPIC	PA166104949	"The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823."	rs12777823 GG	rs12777823 GG	A higher dose of warfarin in African Americans. Calculate warfarin dose using a validated pharmacogenetic algorithm.	1	0	1	-	warfarin	32768	3480
103	CPIC	PA166104949	"The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823."	rs12777823 AA; rs12777823 AG	rs12777823 AA; rs12777823 AG	A lower dose of warfarin in African Americans. Calculate warfarin dose using a validated pharmacogenetic algorithm.	1	0	1	-	warfarin	32768	3480
104	RNPGx	PA166202481	"Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day."	*22	*22	The additional benefit obtained by CYP3A4 (CYP3A4*22) genotyping to adapt the initial tacrolimus dose remains to be assessed (potentially useful test).	1	0	1	CYP3A4	tacrolimus	4366	3127
105	RNPGx	PA166202481	"Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day."	Poor Metabolizer		CYP3A poor metabolizers (PMs) should be given an initial dose of tacrolimus up to a maximum dose of 0.30 mg/kg/day.	0	0	1	CYP3A5	tacrolimus	4368	3127
106	RNPGx	PA166202481	"Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day."	Ultrarapid Metabolizer; Possible Intermediate Metabolizer; Intermediate Metabolizer		CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times.	0	0	1	CYP3A5	tacrolimus	4368	3127
107	RNPGx	PA166202481	"Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day."	*1/*3; *1/*1	*1/*3; *1/*1	"Based on TDM, 1.5 to 2 times the dose recommended to non-expressors; maximum dose 0.30mg/kg/day."	0	0	1	CYP3A5	tacrolimus	4368	3127
108	DPWG	PA166184612	Select an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"- IMMUNOSUPPRESSION: start with 75% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\nNOTE: The percentage of 75% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15.\nNOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\n- LEUKAEMIA: start with 75% of the standard tioguanine dose or start with the standard dose and reduce to 75% if side effects necessitate a dose reduction. It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\nNOTE: The percentage of 75% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15.\nNOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\nNote: more stringent dose reductions are necessary if the patient is also TPMT IM."	1	0	1	NUDT15	thioguanine	13756	3233
109	DPWG	PA166184612	Select an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	Poor Metabolizer		"- avoid thioguanine\n- if it is not possible to avoid tioguanine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. Monitoring should be performed at an increased frequency.\nNOTE: The percentage of 10% is based on the analogy with azathioprine and mercaptopurine and the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. For NUDT15 PM, a percentage of < 20% was calculated for azathioprine and mercaptopurine, but there were insufficient data available to calculate the exact percentage.\nNOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants."	1	1	1	NUDT15	thioguanine	13756	3233
110	RNPGx	PA166127626	"A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of UGT1A1*28 genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the UGT1A1*28/*28 genotype, and that high-dose irinotecan (>=240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype. The French National Network of Pharmacogenetics (RNPGx) included recommendations for irinotecan in  a 2017 paper on several anti-cancer drugs."	*1/*1	*1/*1	UGT1A1 genotyping is advisable for a standard dose (180�230 mg/m2) and essential for intensified dose (> 240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype.	1	0	1	UGT1A1	irinotecan	22969	1725
111	RNPGx	PA166127626	"A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of UGT1A1*28 genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the UGT1A1*28/*28 genotype, and that high-dose irinotecan (>=240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype. The French National Network of Pharmacogenetics (RNPGx) included recommendations for irinotecan in  a 2017 paper on several anti-cancer drugs."	*28/*28	*28/*28	UGT1A1 genotyping is advisable for a standard dose (180�230 mg/m2) and a dose reduction is essential for *28/*28 homozygous patients.	1	0	1	UGT1A1	irinotecan	22969	1725
112	RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	*1; *2; *3	*1; *2; *3	"When there is a risk of hemorrhage due to over exposure in patients carriers of one or more of these alleles, the VKA should be initiated at a lower dose (from 20% to 80% of standard dose). This dose adaptation must also take into account the type of VKA used (warfarin, acenocoumarol or fluindione) because of the variable risk impact, the genotype (CYP2C9 and VKORC1), and other cofactors known to influence exposure to VKAs, including: comedication (statins, sulfonamides, amiodarone, azole antifungals. . .); comorbidities (liver diseases, smoking. . .); individual factors (age, ethnic background); and environmental factors (diet. . .). Algorithms have been developed to optimize dosage as a function of these covariables. Indications for warfarin doses are given by genotype (VKORC1 and CYP2C9) in Table 2. The dose reduction necessary in patients heterozygous for a mutated allele is about 20�40% of the standard dose, but can reach 90% for patients with two or more mutated alleles. Furthermore, longer drug half-life is susceptible to modify the INR monitoring strategy. As an indication, good control of warfarin concentrations (and thus INR) is reached in 7�8 days in extensive metabolizers while it takes 11 days to reach equilibrium in slow metabolizers."	1	0	1	CYP2C9	acenocoumarol	4351	44
113	RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	rs9923231	rs9923231	"When there is a risk of hemorrhage due to over exposure in patients carriers of one or more of these alleles, the VKA should be initiated at a lower dose (from 20% to 80% of standard dose). This dose adaptation must also take into account the type of VKA used (warfarin, acenocoumarol or fluindione) because of the variable risk impact, the genotype (CYP2C9 and VKORC1), and other cofactors known to influence exposure to VKAs, including: comedication (statins, sulfonamides, amiodarone, azole antifungals. . .); comorbidities (liver diseases, smoking. . .); individual factors (age, ethnic background); and environmental factors (diet. . .). Algorithms have been developed to optimize dosage as a function of these covariables. Indications for warfarin doses are given by genotype (VKORC1 and CYP2C9) in Table 2. The dose reduction necessary in patients heterozygous for a mutated allele is about 20�40% of the standard dose, but can reach 90% for patients with two or more mutated alleles. Furthermore, longer drug half-life is susceptible to modify the INR monitoring strategy. As an indication, good control of warfarin concentrations (and thus INR) is reached in 7�8 days in extensive metabolizers while it takes 11 days to reach equilibrium in slow metabolizers."	1	0	1	VKORC1	acenocoumarol	23312	44
114	RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	*1; *2; *3	*1; *2; *3	"When there is a risk of hemorrhage due to over exposure in patients carriers of one or more of these alleles, the VKA should be initiated at a lower dose (from 20% to 80% of standard dose). This dose adaptation must also take into account the type of VKA used (warfarin, acenocoumarol or fluindione) because of the variable risk impact, the genotype (CYP2C9 and VKORC1), and other cofactors known to influence exposure to VKAs, including: comedication (statins, sulfonamides, amiodarone, azole antifungals. . .); comorbidities (liver diseases, smoking. . .); individual factors (age, ethnic background); and environmental factors (diet. . .). Algorithms have been developed to optimize dosage as a function of these covariables. Indications for warfarin doses are given by genotype (VKORC1 and CYP2C9) in Table 2. The dose reduction necessary in patients heterozygous for a mutated allele is about 20�40% of the standard dose, but can reach 90% for patients with two or more mutated alleles. Furthermore, longer drug half-life is susceptible to modify the INR monitoring strategy. As an indication, good control of warfarin concentrations (and thus INR) is reached in 7�8 days in extensive metabolizers while it takes 11 days to reach equilibrium in slow metabolizers."	1	0	1	CYP2C9	fluindione	4351	1378
115	RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	rs9923231	rs9923231	"When there is a risk of hemorrhage due to over exposure in patients carriers of one or more of these alleles, the VKA should be initiated at a lower dose (from 20% to 80% of standard dose). This dose adaptation must also take into account the type of VKA used (warfarin, acenocoumarol or fluindione) because of the variable risk impact, the genotype (CYP2C9 and VKORC1), and other cofactors known to influence exposure to VKAs, including: comedication (statins, sulfonamides, amiodarone, azole antifungals. . .); comorbidities (liver diseases, smoking. . .); individual factors (age, ethnic background); and environmental factors (diet. . .). Algorithms have been developed to optimize dosage as a function of these covariables. Indications for warfarin doses are given by genotype (VKORC1 and CYP2C9) in Table 2. The dose reduction necessary in patients heterozygous for a mutated allele is about 20�40% of the standard dose, but can reach 90% for patients with two or more mutated alleles. Furthermore, longer drug half-life is susceptible to modify the INR monitoring strategy. As an indication, good control of warfarin concentrations (and thus INR) is reached in 7�8 days in extensive metabolizers while it takes 11 days to reach equilibrium in slow metabolizers."	1	0	1	VKORC1	fluindione	23312	1378
116	RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	*1; *2; *3	*1; *2; *3	"When there is a risk of hemorrhage due to over exposure in patients carriers of one or more of these alleles, the VKA should be initiated at a lower dose (from 20% to 80% of standard dose). This dose adaptation must also take into account the type of VKA used (warfarin, acenocoumarol or fluindione) because of the variable risk impact, the genotype (CYP2C9 and VKORC1), and other cofactors known to influence exposure to VKAs, including: comedication (statins, sulfonamides, amiodarone, azole antifungals. . .); comorbidities (liver diseases, smoking. . .); individual factors (age, ethnic background); and environmental factors (diet. . .). Algorithms have been developed to optimize dosage as a function of these covariables. Indications for warfarin doses are given by genotype (VKORC1 and CYP2C9) in Table 2. The dose reduction necessary in patients heterozygous for a mutated allele is about 20�40% of the standard dose, but can reach 90% for patients with two or more mutated alleles. Furthermore, longer drug half-life is susceptible to modify the INR monitoring strategy. As an indication, good control of warfarin concentrations (and thus INR) is reached in 7�8 days in extensive metabolizers while it takes 11 days to reach equilibrium in slow metabolizers."	1	0	1	CYP2C9	warfarin	4351	3480
117	RNPGx	PA166202621	Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.	rs9923231	rs9923231	"When there is a risk of hemorrhage due to over exposure in patients carriers of one or more of these alleles, the VKA should be initiated at a lower dose (from 20% to 80% of standard dose). This dose adaptation must also take into account the type of VKA used (warfarin, acenocoumarol or fluindione) because of the variable risk impact, the genotype (CYP2C9 and VKORC1), and other cofactors known to influence exposure to VKAs, including: comedication (statins, sulfonamides, amiodarone, azole antifungals. . .); comorbidities (liver diseases, smoking. . .); individual factors (age, ethnic background); and environmental factors (diet. . .). Algorithms have been developed to optimize dosage as a function of these covariables. Indications for warfarin doses are given by genotype (VKORC1 and CYP2C9) in Table 2. The dose reduction necessary in patients heterozygous for a mutated allele is about 20�40% of the standard dose, but can reach 90% for patients with two or more mutated alleles. Furthermore, longer drug half-life is susceptible to modify the INR monitoring strategy. As an indication, good control of warfarin concentrations (and thus INR) is reached in 7�8 days in extensive metabolizers while it takes 11 days to reach equilibrium in slow metabolizers."	1	0	1	VKORC1	warfarin	23312	3480
118	RNPGx	PA166202721	"The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency."	Poor Metabolizer		Dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.	1	1	1	DPYD	capecitabine	5039	655
119	RNPGx	PA166202721	"The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency."	Intermediate Metabolizer		Dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.	1	0	1	DPYD	fluorouracil	5039	1390
120	CPNDS	PA166122666	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of CYP2D6 genotype when prescribing codeine. They recommend that poor metabolizers of CYP2D6 should not receive codeine for pain relief, and ultrametabolizers of CYP2D6 should avoid codeine for pain relief."	Intermediate Metabolizer		"In individuals with IM (intermediate metabolizer) or EM (extensive metabolizer) CYP2D6 genotypes, codeine can be used as per standard of care. Existing evidence suggests that caution is still warranted in CYP2D6 EMs receiving codeine if they are receiving maximal therapeutic doses of codeine and have additional risk factors for toxicity."	1	0	1	CYP2D6	codeine	4352	854
121	RNPGx	PA166202701	"The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends CYP2D6 and CYP2C19 genotyping before initiating an antidepressant treatment, especially in patients with a high risk of toxicity."	Likely Intermediate Metabolizer; Intermediate Metabolizer; Likely Poor Metabolizer; Poor Metabolizer		"Due to the risk of adverse effects that would require discontinuation of treatment, antidepressants should be avoided for patients exhibiting complete deficiency. Dose reduction to the order of 25-50% of standard dose can be proposed for patients with partial deficiency.\nDue to the current lack of biomarkers predictive of response or non-response to antidepressants, these tests can potentially be used to optimize treatment while limiting adverse effects."	1	1	1	CYP2C19	antidepressants	4349	280
122	RNPGx	PA166202701	"The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends CYP2D6 and CYP2C19 genotyping before initiating an antidepressant treatment, especially in patients with a high risk of toxicity."	Intermediate Metabolizer; Poor Metabolizer		"Due to the risk of adverse effects that would require discontinuation of treatment, antidepressants should be avoided for patients exhibiting complete deficiency. Dose reduction to the order of 25-50% of standard dose can be proposed for patients with partial deficiency.\nDue to the current lack of biomarkers predictive of response or non-response to antidepressants, these tests can potentially be used to optimize treatment while limiting adverse effects."	1	1	1	CYP2D6	antidepressants	4352	280
123	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Intermediate Metabolizer		"For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	1	0	1	HLA-B	fosphenytoin	8015	1430
124	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Intermediate Metabolizer		"For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	1	0	1	HLA-B	phenytoin	8015	2604
125	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Poor Metabolizer		"For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	1	0	1	HLA-B	fosphenytoin	8015	1430
126	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Poor Metabolizer		"For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	1	0	1	HLA-B	phenytoin	8015	2604
127	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Intermediate Metabolizer		"For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	1	0	1	CYP2C9	fosphenytoin	4351	1430
128	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Intermediate Metabolizer		"For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	1	0	1	CYP2C9	phenytoin	4351	2604
129	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Poor Metabolizer		"For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	1	0	1	CYP2C9	fosphenytoin	4351	1430
130	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Poor Metabolizer		"For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	1	0	1	CYP2C9	phenytoin	4351	2604
131	DPWG	PA166184613	Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"- IMMUNOSUPPRESSION:start with 50% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy.\nNote: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of < 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.\nNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\n- LEUKAEMIA: start at 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction. It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\nNote: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of < 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.\nNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\nNote: more stringent dose reductions are necessary if the patient is also TPMT IM or TPMT PM."	0	0	1	NUDT15	mercaptopurine	13756	1994
132	DPWG	PA166184613	Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	Poor Metabolizer		"Avoid azathioprine and mercaptopurine.  If it is not possible to avoid azathioprine and mercaptopurine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur. Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy.\nNote: The percentage of 10% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of < 20% was calculated for NUDT15 PM, but there were insufficient data available to calculate the exact percentage.\nNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants."	1	0	1	NUDT15	mercaptopurine	13756	1994
133	DPWG	PA166104989	"The Dutch Pharmacogenetics Working Group Guideline for atomoxetine states for CYP2D6 ultrarapid metabolizers, to be alert to reduced efficacy of atomoxetine or select an alternative drug as a precaution.  Be alert to ADEs in CYP2D6 poor metabolizers."	Intermediate Metabolizer		1. In the event of side effects occurring and/or a response later than 9 weeks: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 2-3 times higher for IM than for EM at the same dose.	0	0	1	CYP2D6	atomoxetine	4352	413
134	CPIC	PA166122686	"The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction."	Intermediate Metabolizer		Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).  Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose.	0	0	1	DPYD	fluorouracil	5039	1390
135	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Intermediate Metabolizer		Reduce starting dose by 50% followed by titration of dose based on toxicity or pharmacokinetics	0	0	1	DPYD	capecitabine	5039	655
136	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Intermediate Metabolizer		Reduce starting dose by 50% followed by titration of dose based on toxicity or pharmacokinetics	0	0	1	DPYD	fluorouracil	5039	1390
137	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Intermediate Metabolizer		Reduce starting dose by 50% followed by titration of dose based on toxicity or pharmacokinetics	0	0	1	DPYD	tegafur	5039	3158
138	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Poor Function		"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy)."	0	1	1	SLCO1B1	rosuvastatin	19487	2890
139	DPWG	PA166104964	"The Dutch Pharmacogenetics Working Group Guideline for clomipramine recommends dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer."	Ultrarapid Metabolizer		"Use 1.5 times the standard dose and monitor the effect and side effects of the plasma concentrations of clomipramine and desmethylclomipramine to set the maintenance dose. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. If a dose increase is not wanted due to potential cardiotoxic hydroxy metabolites: avoid clomipramine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline."	1	0	1	CYP2D6	clomipramine	4352	838
140	DPWG	PA166104964	"The Dutch Pharmacogenetics Working Group Guideline for clomipramine recommends dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer."	Intermediate Metabolizer		"Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mLFor obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic."	0	0	1	CYP2D6	clomipramine	4352	838
141	DPWG	PA166104964	"The Dutch Pharmacogenetics Working Group Guideline for clomipramine recommends dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer."	Poor Metabolizer		"Indication DEPRESSION: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. The therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. Values higher than 600 ng/mL are considered toxic. Indication ANXIETY DISORDERS or OBSESSIVE COMPULSIVE DISORDER: if side effects occur: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear while the effectiveness is retained. Clomipramine and desmethylclomipramine both contribute to the side effects. Only clomipramine contributes to the effectiveness. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic, whilst the therapeutic upper limit for depression is 400 ng/mL. If dose reduction does not have the desired effect: avoid clomipramine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline."	1	0	1	CYP2D6	clomipramine	4352	838
142	CPIC	PA166105002	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers."	Intermediate Metabolizer		Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	0	0	1	CYP2D6	desipramine	4352	1005
143	DPWG	PA166182819	Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.	Intermediate Metabolizer		Use no more than the following doses (80% of the standard maximum dose):\n12 years and older: 16 mg/day\nyounger than 12 years: 0.08 mg/kg per day to a maximum of 3 mg/day	0	0	1	CYP2D6	pimozide	4352	2619
144	DPWG	PA166182819	Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.	Poor Metabolizer		Use no more than the following doses (50% of the standard maximum dose):\n12 years and older: 10 mg/day\nyounger than 12 years: 0.05 mg/kg per day to a maximum of 2 mg/day	0	0	1	CYP2D6	pimozide	4352	2619
145	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	0	0	1	CYP2D6	doxepin	4352	1126
146	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	0	0	1	CYP2D6	trimipramine	4352	3339
147	DPWG	PA166104962	"Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor propafenone plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers."	Poor Metabolizer		"Reduce the dose to 30% of the standard dose, perform an ECG and monitor plasma concentrations."	0	0	1	CYP2D6	propafenone	4352	2730
148	DPWG	PA166104972	"CYP2D6 poor metabolizers should receive 30% of the standard dose of imipramine, CYP2D6 intermediate metabolizers should receive 70% of the standard dose, and CYP2D6 ultra-rapid metabolizers should receive 1.7 times the standard dose. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose."	Poor Metabolizer		Use 30% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.	0	0	1	CYP2D6	imipramine	4352	1648
149	DPWG	PA166104972	"CYP2D6 poor metabolizers should receive 30% of the standard dose of imipramine, CYP2D6 intermediate metabolizers should receive 70% of the standard dose, and CYP2D6 ultra-rapid metabolizers should receive 1.7 times the standard dose. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose."	Intermediate Metabolizer		Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.	0	0	1	CYP2D6	imipramine	4352	1648
150	DPWG	PA166104972	"CYP2D6 poor metabolizers should receive 30% of the standard dose of imipramine, CYP2D6 intermediate metabolizers should receive 70% of the standard dose, and CYP2D6 ultra-rapid metabolizers should receive 1.7 times the standard dose. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose."	Ultrarapid Metabolizer		"Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline."	1	0	1	CYP2D6	imipramine	4352	1648
151	DPWG	PA166104952	Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	Intermediate Metabolizer		"-IMMUNOSUPPRESSION\nStart with 50% of the standard dose. Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. Dose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.\n-LEUKAEMIA:\nstart with 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction\nIt is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. The initial dose should be adjusted based on toxicity (monitoring of the blood counts) and efficacy.\nNote: more stringent dose reductions are necessary if the patient is also NUDT15 IM or NUDT15 PM."	0	0	1	TPMT	mercaptopurine	22019	1994
152	DPWG	PA166104960	Select an alternative drug or reduce the initial dose of thioguanine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	Intermediate Metabolizer		"- IMMUNOSUPPRESSION: Start with 75% of the standard dose.  Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. The frequency of monitoring should be increased.\n- LEUKAEMIA: Start with 75% of the standard thioguanine dose, or start with the standard dose and reduce to 75% if side effects necessitate a dose reduction.  It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity.  The initial dose should be adjusted based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\nNote: more stringent dose reductions are necessary if the patient is also NUDT15 IM."	0	0	1	TPMT	thioguanine	22019	3233
153	DPWG	PA166211021	"The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype."	*1/*3	*1/*3	"Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For this genetic variation, a moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model."	0	0	1	CYP2C9	siponimod	4351	2982
154	DPWG	PA166211021	"The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype."	*2/*3	*2/*3	"Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For this genetic variation, a moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model."	0	0	1	CYP2C9	siponimod	4351	2982
155	DPWG	PA166211021	"The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype."	Intermediate Metabolizer		"Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For the comparable genetic variation *1/*3, the moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model."	0	0	1	CYP2C9	siponimod	4351	2982
156	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Normal Metabolizer		"Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents.  Allow at least 2 weeks to reach steady-state after each dose adjustment."	0	0	1	TPMT	mercaptopurine	22019	1994
157	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"Start with reduced starting doses (30-80% of normal dose) if normal starting dose is > or = 75 mg/m2/day or > or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."	0	0	1	TPMT	mercaptopurine	22019	1994
158	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Possible Intermediate Metabolizer		"Start with reduced starting doses (30-80% of normal dose) if normal starting dose is > or = 75 mg/m2/day or > or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended."	0	0	1	TPMT	mercaptopurine	22019	1994
159	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Normal Metabolizer		"Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents.  Allow at least 2 weeks to reach steady-state after each dose adjustment."	0	0	1	NUDT15	mercaptopurine	13756	1994
160	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"Start with reduced starting doses (30-80% of normal dose) if normal starting dose is > or = 75 mg/m2/day or > or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or 1.5 mg/kg/day, dose reduction may not be recommended."	0	0	1	NUDT15	mercaptopurine	13756	1994
161	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Possible Intermediate Metabolizer		"Start with reduced starting doses (30-80% of normal dose) if normal starting dose is > or = 75 mg/m2/day or > or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or 1.5 mg/kg/day, dose reduction may not be recommended."	0	0	1	NUDT15	mercaptopurine	13756	1994
162	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Ultrarapid Metabolizer		Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	lansoprazole	4349	1790
163	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Ultrarapid Metabolizer		Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	omeprazole	4349	2271
164	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Ultrarapid Metabolizer		Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	pantoprazole	4349	2503
165	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Rapid Metabolizer		Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	lansoprazole	4349	1790
166	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Rapid Metabolizer		Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	omeprazole	4349	2271
167	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Rapid Metabolizer		Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	pantoprazole	4349	2503
168	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Normal Metabolizer		Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	lansoprazole	4349	1790
169	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Normal Metabolizer		Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	omeprazole	4349	2271
170	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Normal Metabolizer		Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	pantoprazole	4349	2503
171	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Likely Intermediate Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	lansoprazole	4349	1790
172	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Likely Intermediate Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	omeprazole	4349	2271
173	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Likely Intermediate Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	pantoprazole	4349	2503
174	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	lansoprazole	4349	1790
175	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	omeprazole	4349	2271
176	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	pantoprazole	4349	2503
177	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Likely Poor Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	lansoprazole	4349	1790
178	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Likely Poor Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	omeprazole	4349	2271
179	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Likely Poor Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	pantoprazole	4349	2503
180	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Poor Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	lansoprazole	4349	1790
181	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Poor Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	omeprazole	4349	2271
182	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Poor Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	1	CYP2C19	pantoprazole	4349	2503
183	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	0	0	1	CYP2D6	imipramine	4352	1648
184	CPIC	PA166176068	"The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy."	Normal Metabolizer	AS 1	"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:26211827, 24881463]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:27226358]. Avoid CYP2D6 strong to weak inhibitors."	1	0	1	CYP2D6	tamoxifen	4352	3137
185	CPIC	PA166176068	"The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy."	Intermediate Metabolizer	AS 1	"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:26211827, 24881463]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:27226358]. Avoid CYP2D6 strong to weak inhibitors."	1	0	1	CYP2D6	tamoxifen	4352	3137
186	CPIC	PA166176068	"The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy."	Normal Metabolizer + *10	AS 1	"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:26211827, 24881463]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:27226358]. Avoid CYP2D6 strong to weak inhibitors."	1	0	1	CYP2D6	tamoxifen	4352	3137
187	CPIC	PA166176068	"The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy."	Intermediate Metabolizer + *10	AS 1	"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:26211827, 24881463]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:27226358]. Avoid CYP2D6 strong to weak inhibitors."	1	0	1	CYP2D6	tamoxifen	4352	3137
188	CPIC	PA166176068	"The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy."	Intermediate Metabolizer	AS 0.5	"Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:26211827, 24881463]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:27226358]. Avoid CYP2D6 strong to weak inhibitors."	1	0	1	CYP2D6	tamoxifen	4352	3137
189	CPIC	PA166182603	Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.	Intermediate Metabolizer		Consider initiating efavirenz with decreased dose of 400 mg/day.	0	0	1	CYP2B6	efavirenz	4346	1186
190	CPIC	PA166182603	Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.	Poor Metabolizer		Consider initiating efavirenz with decreased dose of 400 or 200 mg/day.	0	0	1	CYP2B6	efavirenz	4346	1186
191	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	Normal risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	amikacin	12748	173
192	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	Normal risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	gentamicin	12748	1476
193	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	Normal risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	kanamycin	12748	1768
194	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	Normal risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	paromomycin	12748	2519
195	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	Normal risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	plazomicin	12748	2651
196	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	Normal risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	streptomycin	12748	3052
197	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	Normal risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	tobramycin	12748	3278
198	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	uncertain risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic drug monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	amikacin	12748	173
199	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	uncertain risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic drug monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	gentamicin	12748	1476
200	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	uncertain risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic drug monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	kanamycin	12748	1768
201	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	uncertain risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic drug monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	paromomycin	12748	2519
202	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	uncertain risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic drug monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	plazomicin	12748	2651
203	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	uncertain risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic drug monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	streptomycin	12748	3052
204	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	uncertain risk of aminoglycoside-induced hearing loss		Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic drug monitoring. Evaluate regularly for hearing loss in line with local guidance.	0	1	1	MT-RNR1	tobramycin	12748	3278
205	DPWG	PA166104957	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose."	Ultrarapid Metabolizer		"For Helicobacter pylori ERADICATION THERAPY: 1. use a 3-fold higher dose. 2. advise the patient to contact their doctor if symptoms of dyspepsia persist.\nOTHER INDICATIONS: 1. be alert to reduced effectiveness. 2. if necessary, use a 3-fold higher dose. 3. advise the patient to report persisting symptoms of dyspepsia."	0	0	1	CYP2C19	omeprazole	4349	2271
206	DPWG	PA166104987	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose."	Ultrarapid Metabolizer		"For Helicobacter pylori ERADICATION THERAPY: 1. Use a 4-fold higher dose. 2. Advise the patient to contact their doctor if symptoms of dyspepsia persist.\nOTHER INDICATIONS: 1. Be alert to reduced effectiveness. 2. If necessary, use a 4-fold higher dose. 3. Advise the patient to report persisting symptoms of dyspepsia."	0	0	1	CYP2C19	lansoprazole	4349	1790
207	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	0	0	1	CYP2D6	amitriptyline	4352	195
208	DPWG	PA166182842	"Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. ""The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins"""	Intermediate Metabolizer		"1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *1/*2 or *1/*3 is present. See Algorithms coumarins for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage."	0	0	1	CYP2C9	warfarin	4351	3480
209	DPWG	PA166182842	"Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. ""The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins"""	Poor Metabolizer		"1. use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *2 or *3 is present. See Algorithms coumarins for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage."	0	0	1	CYP2C9	warfarin	4351	3480
210	DPWG	PA166182842	"Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. ""The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins"""	*1/*3	*1/*3	"1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins. From day 6 on the standard algorithm without genotype information can be used to calculate the dose."	0	0	1	CYP2C9	warfarin	4351	3480
211	DPWG	PA166182842	"Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. ""The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins"""	*2/*2	*2/*2	"1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins. From day 6 on the standard algorithm without genotype information can be used to calculate the dose."	0	0	1	CYP2C9	warfarin	4351	3480
212	DPWG	PA166182842	"Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. ""The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins"""	*2/*3	*2/*3	"1. use 45% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins. From day 6 on the standard algorithm without genotype information can be used to calculate the dose."	0	0	1	CYP2C9	warfarin	4351	3480
213	DPWG	PA166182842	"Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. ""The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins"""	*3/*3	*3/*3	"1. use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins. From day 6 on the standard algorithm without genotype information can be used to calculate the dose."	0	0	1	CYP2C9	warfarin	4351	3480
214	DPWG	PA166104982	The Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.	Ultrarapid Metabolizer		"1. increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites.  Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\n2. if a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline."	1	0	1	CYP2D6	amitriptyline	4352	195
215	DPWG	PA166104982	The Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.	Intermediate Metabolizer		Use 75% of the standard dose and monitor the efficacy and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose	0	0	1	CYP2D6	amitriptyline	4352	195
216	DPWG	PA166104982	The Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.	Poor Metabolizer		Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose	0	0	1	CYP2D6	amitriptyline	4352	195
217	DPWG	PA166104992	"For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose or select an alternative drug that is not metabolized by CYP2D6. For ultrarapid metabolizers, be alert to low zuclopenthixol plasma concentrations and, if necessary, increase the dose or select an alternative drug."	Ultrarapid Metabolizer		There is insufficient information available to make a dosage recommendation. - if the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the standard dose.	0	0	1	CYP2D6	zuclopenthixol	4352	3528
218	DPWG	PA166104992	"For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose or select an alternative drug that is not metabolized by CYP2D6. For ultrarapid metabolizers, be alert to low zuclopenthixol plasma concentrations and, if necessary, increase the dose or select an alternative drug."	Intermediate Metabolizer		Use 75% of the standard dose.	0	0	1	CYP2D6	zuclopenthixol	4352	3528
219	DPWG	PA166104992	"For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose or select an alternative drug that is not metabolized by CYP2D6. For ultrarapid metabolizers, be alert to low zuclopenthixol plasma concentrations and, if necessary, increase the dose or select an alternative drug."	Poor Metabolizer		Use with 50% of the standard dose.	0	0	1	CYP2D6	zuclopenthixol	4352	3528
220	DPWG	PA166104977	The Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.	Intermediate Metabolizer		"Do not exceed the following daily doses:\n1. Adults up to 65 years: 30mg as tablets or 22mg as drops,\n2. Adults 65 years or older: 15mg as tablets or 10mg as drops"	0	0	1	CYP2C19	citalopram	4349	819
221	DPWG	PA166104977	The Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.	Poor Metabolizer		"Do not exceed the following daily doses (50% of the standard maximum dose):\n1. adults up to 65 years: 20mg as tablets or 16mg as drops,\n2. Adults 65 years or older: 10mg as tablets or 8mg as drops"	0	0	1	CYP2C19	citalopram	4349	819
222	DPWG	PA166104951	"Dose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count."	Poor Metabolizer		"Start with 70% of the standard dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count."	0	0	1	UGT1A1	irinotecan	22969	1725
223	DPWG	PA166104990	"Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers."	Poor Metabolizer		Use 50% of the standard dose and monitor the plasma concentration.	0	0	1	CYP2C19	voriconazole	4349	3473
224	DPWG	PA166104990	"Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers."	Ultrarapid Metabolizer		Use an initial dose that is 1.5x higher and monitor the plasma concentration.	0	0	1	CYP2C19	voriconazole	4349	3473
225	DPWG	PA166104994	"The Dutch Pharmacogenetics Working Group Guideline for doxepin recommends dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM."	Ultrarapid Metabolizer		"Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic. If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline."	1	0	1	CYP2D6	doxepin	4352	1126
226	DPWG	PA166104994	"The Dutch Pharmacogenetics Working Group Guideline for doxepin recommends dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM."	Intermediate Metabolizer		Use 80% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.	0	0	1	CYP2D6	doxepin	4352	1126
227	DPWG	PA166104994	"The Dutch Pharmacogenetics Working Group Guideline for doxepin recommends dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM."	Poor Metabolizer		Use 40% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.	0	0	1	CYP2D6	doxepin	4352	1126
228	DPWG	PA166104968	"For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine."	Ultrarapid Metabolizer		"1. be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine\n2. if necessary, increase the dose to 150% of the standard dose\n3. if dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided\nAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline."	1	0	1	CYP2D6	venlafaxine	4352	3423
229	DPWG	PA166104980	"Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration."	Poor Metabolizer		Do not give doses exceeding 75 mg/day. Guide the dose by response and side effects and/or sertraline plasma concentration.	0	0	1	CYP2C19	sertraline	4349	2963
230	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy."	0	0	1	CYP2C9	celecoxib	4351	736
231	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy."	0	0	1	CYP2C9	flurbiprofen	4351	1400
232	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy."	0	0	1	CYP2C9	ibuprofen	4351	1621
233	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy."	0	0	1	CYP2C9	lornoxicam	4351	1890
234	DPWG	PA166104983	Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor.	Heterozygote		"Liver transplantation: In addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.\nLIVER is also of the genotype HETEROZYGOUS EXPRESSOR: Use 1.5 times the normal initial dose. Adjustment of the dose should then be based on therapeutic drug monitoring.\nIf LIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation. Other indications: Use 1.5 times the initial dose that would yield the desired result in non-expressers. Adjustment of the dose should then be based on therapeutic drug monitoring.\nFor example: A Dutch study found a median trough concentration for tacrolimus of 14.7 ng/mL after 3 days at an initial dose of 0.15 mg/kg twice daily for 29 kidney transplant patients who were heterozygous expressers. Their target value was 10 - 15 ng/mL."	0	0	1	CYP3A5	tacrolimus	4368	3127
235	DPWG	PA166104983	Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor.	Homozygous		"Liver transplantation: In addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.\nLIVER is also of the genotype HOMOZYGOUS EXPRESSOR: Use 2.5 times the normal initial dose. Adjustment of the dose should then be based on therapeutic drug monitoring.\nLIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation. Other indications: Use 2.5 times the initial dose that would yield the desired result in non-expressers. Adjustment of the dose should then be based on therapeutic drug monitoring.\nFor example: One Dutch study found a median trough concentration for tacrolimus after three days of 9.4 ng/mL at an initial dose of 0.15 mg/kg twice daily for 5 homozygous kidney transplant patients. Their target value was 10 - 15 ng/mL."	0	0	1	CYP3A5	tacrolimus	4368	3127
236	DPWG	PA166104983	Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor.	Heterozygote		"Liver transplantation: In addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.\nLIVER is also of the genotype HETEROZYGOUS EXPRESSOR: Start with 1.75 times the standard initial dose Adjustment of the dose should then be based on therapeutic drug monitoring.\nIf LIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation. Other indications: Start with 1.75 times of the standard initial dose that would yield the desired result in non-expressors. Adjustment of the dose should then be based on therapeutic drug monitoring."	0	0	1	CYP3A5	tacrolimus	4368	3127
237	DPWG	PA166104983	Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor.	Homozygous		"Liver transplantation: In addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.\nLIVER is also of the genotype HOMOZYGOUS EXPRESSOR: Start with 2.5 times the standard initial dose Adjustment of the dose should then be based on therapeutic drug monitoring.\nLIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation. Other indications: Start with 2.5 times the standard initial dose that would yield the desired result in non-expressors Adjustment of the dose should then be based on therapeutic drug monitoring."	0	0	1	CYP3A5	tacrolimus	4368	3127
238	DPWG	PA166104961	"The Dutch Pharmacogenetics Working Group Guideline for nortriptyline recommends a dose reduction for CYP2D6 poor or intermediate metabolizer patients. For CYP2D6 ultrarapid metabolizers, select an alternative drug or use 1.7 times the standard dose. Monitoring of nortriptyline and 10-hydroxynortriptyline plasma concentrations is recommended."	Ultrarapid Metabolizer		"Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline and be alert to an increase in the plasma concentration of the cardiotoxic metabolite Z-10-hydroxynortriptyline. Plasma concentrations of Z-hydroxynortriptyline exceeding 40 ng/mL are considered toxic.\nIf a dose increase is not wanted due to the cardiotoxic hydroxy metabolite: avoid nortriptyline. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline."	1	0	1	CYP2D6	nortriptyline	4352	2240
239	DPWG	PA166104961	"The Dutch Pharmacogenetics Working Group Guideline for nortriptyline recommends a dose reduction for CYP2D6 poor or intermediate metabolizer patients. For CYP2D6 ultrarapid metabolizers, select an alternative drug or use 1.7 times the standard dose. Monitoring of nortriptyline and 10-hydroxynortriptyline plasma concentrations is recommended."	Intermediate Metabolizer		Use 60% of the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline in order to set the maintenance dose.\nThe therapeutic range of nortriptyline is 50-150 ng/mL. Values exceeding 250 ng/mL are considered toxic.	0	0	1	CYP2D6	nortriptyline	4352	2240
240	DPWG	PA166104961	"The Dutch Pharmacogenetics Working Group Guideline for nortriptyline recommends a dose reduction for CYP2D6 poor or intermediate metabolizer patients. For CYP2D6 ultrarapid metabolizers, select an alternative drug or use 1.7 times the standard dose. Monitoring of nortriptyline and 10-hydroxynortriptyline plasma concentrations is recommended."	Poor Metabolizer		Use 40% of the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline in order to set the maintenance dose.\nThe therapeutic range of nortriptyline is 50-150 ng/mL. Values exceeding 250 ng/mL are considered toxic.	0	0	1	CYP2D6	nortriptyline	4352	2240
241	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Normal Metabolizer		"Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment."	0	0	1	TPMT	azathioprine	22019	432
242	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"Start with reduced starting doses (30-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment."	0	0	1	TPMT	azathioprine	22019	432
243	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Possible Intermediate Metabolizer		"Start with reduced starting doses (30-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment."	0	0	1	TPMT	azathioprine	22019	432
244	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Normal Metabolizer		"Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment."	0	0	1	NUDT15	azathioprine	13756	432
245	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"Start with reduced starting doses (30-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment."	0	0	1	NUDT15	azathioprine	13756	432
246	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Possible Intermediate Metabolizer		"Start with reduced starting doses (30-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment."	0	0	1	NUDT15	azathioprine	13756	432
247	DPWG	PA166104934	Select an alternative drug or reduce the initial dose of azathioprine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.	Intermediate Metabolizer		-IMMUNOSUPPRESSION\nStart with 50% of the standard dose\nAdjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.\nDose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.\nNote: more stringent dose reductions are necessary if the patient is also NUDT15 IM or NUDT15 PM.	0	0	1	TPMT	azathioprine	22019	432
248	CPIC	PA166109594	"The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction."	Intermediate Metabolizer		Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose.	0	0	1	DPYD	capecitabine	5039	655
249	DPWG	PA166264961	Patients with the GT or TT genotypes at rs2231142 should be given an increased dose of allopurinol.	141KK (TT genotype)	rs2231142 TT	"Use 1.4 times the standard dose. This equates to a dose titration schedule of 100, 300, 400, 600 and 700 mg/day instead of the usual schedule of 100, 200, 300, 400 and 500 mg/day."	0	0	1	ABCG2	allopurinol	83	127
250	DPWG	PA166264961	Patients with the GT or TT genotypes at rs2231142 should be given an increased dose of allopurinol.	141QK (GT genotype)	rs2231142 GT	"Use 1.25 times the standard dose. This equates to a dose titration schedule of 100, 200, 400 and 500 mg/day instead of the usual schedule of 100, 200, 300 and 400 mg/day."	0	0	1	ABCG2	allopurinol	83	127
251	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Normal Metabolizer		Start with normal starting dose (e.g. 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine.  Allow 2 weeks to reach steady-state after each dose adjustment.	0	0	1	TPMT	thioguanine	22019	3233
252	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is > or = 40-60 mg/m2/day (e.g. 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents."	0	0	1	TPMT	thioguanine	22019	3233
253	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Possible Intermediate Metabolizer		"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is > or = 40-60 mg/m2/day (e.g. 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents."	0	0	1	TPMT	thioguanine	22019	3233
254	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Normal Metabolizer		Start with normal starting dose (40-60 mg/day).  Adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine.  Allow 2 weeks to reach steady-state after each dose adjustment.	0	0	1	NUDT15	thioguanine	13756	3233
255	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is > or = 40-60 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents."	0	0	1	NUDT15	thioguanine	13756	3233
256	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Possible Intermediate Metabolizer		"Start with reduced doses (50% to 80% of normal dose) if normal starting dose is > or = 40-60 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents."	0	0	1	NUDT15	thioguanine	13756	3233
257	DPWG	PA166104943	The Dutch Pharmacogenetics Working Group Guideline for risperidone recommends decreasing the dose for CYP2D6 poor metabolizers and using an alternative drug or titrate the dose according to the maximum dose for the active metabolite for CYP2D6 ultrarapid metabolizers.	Poor Metabolizer		"Use 67% of the standard dose. If problematic side effects originating in the central nervous system occur despite this reduced dose, then reduce the dose further to 50% of the standard dose."	0	0	1	CYP2D6	risperidone	4352	2871
258	CPIC	PA166104998	"The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers."	Intermediate Metabolizer		Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	0	0	1	CYP2D6	nortriptyline	4352	2240
259	CPIC	PA166104948	The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)	Ultrarapid Metabolizer		"If considering clopidogrel, use at standard dose (75 mg/day)"	0	0	1	CYP2C19	clopidogrel	4349	842
260	CPIC	PA166104948	The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)	Rapid Metabolizer		"If considering clopidogrel, use at standard dose (75 mg/day)"	0	0	1	CYP2C19	clopidogrel	4349	842
261	CPIC	PA166104948	The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)	Normal Metabolizer		"If considering clopidogrel, use at standard dose (75 mg/day)"	0	0	1	CYP2C19	clopidogrel	4349	842
262	CPIC	PA166104948	The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)	Likely Intermediate Metabolizer		Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	1	0	1	CYP2C19	clopidogrel	4349	842
263	CPIC	PA166104948	The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)	Intermediate Metabolizer		Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	1	0	1	CYP2C19	clopidogrel	4349	842
264	CPIC	PA166104948	The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)	Likely Poor Metabolizer		Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	1	0	1	CYP2C19	clopidogrel	4349	842
265	CPIC	PA166104948	The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)	Poor Metabolizer		Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.	1	0	1	CYP2C19	clopidogrel	4349	842
266	DPWG	PA166104958	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose."	Ultrarapid Metabolizer		"For Helicobacter pylori ERADICATION THERAPY: 1. use a 5-fold higher dose. 2. advise the patient to contact their doctor if symptoms of dyspepsia persist.\nOTHER INDICATIONS: 1. be alert to reduced effectiveness. 2. if necessary, use a 5-fold higher dose. 3. advise the patient to report persisting symptoms of dyspepsia."	0	0	1	CYP2C19	pantoprazole	4349	2503
267	DPWG	PA166182846	"Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the *5/*6, *5/*18 or other CYP2B6 IM genotypes, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed."	Intermediate Metabolizer		"1. Determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed. In 14 IM adults, a dose reduction to 400 mg/day (2/3rd of the standard dose) was sufficient to achieve therapeutic plasma concentrations and to reduce or resolve side effects. The therapeutic range established for efavirenz is 1000-4000 ng/ml."	0	0	1	CYP2B6	efavirenz	4346	1186
268	DPWG	PA166182846	"Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the *5/*6, *5/*18 or other CYP2B6 IM genotypes, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed."	Poor Metabolizer		"* Efavirenz in MONOpreparation, adults and children FROM 40 KG: Body mass index LESS THAN or EQUAL to 25: 1. The recommended initial dose is 400 mg/day and this dose should be titrated to plasma concentration if needed (further reduction to 200 mg/day or in rare cases an increase to 600 mg/day). The therapeutic range established for efavirenz is 1000-4000 ng/ml. Body mass index GREATER than 25: 1. The recommended initial dose is 600 mg/day and this dose should be titrated to plasma concentration if needed (reduction to 400 or 200 mg/day). The therapeutic range established for efavirenz is 1000-4000 ng/ml.\n*Efavirenz in MONOpreparation, children LIGHTER THAN 40 KG: 1. Start with the standard dose and titrate this dose to plasma concentration if needed. In adults, therapeutic plasma concentrations were achieved at either 2/3rd of the standard dose (1/3rd of the patients) or 1/3rd of the standard dose (2/3rd of the patients). In children younger than 3 years, therapeutic plasma concentrations were achieved at doses of approximately 10 mg/kg per day (as capsules) (100 mg/day for 7-14 kg and 150 mg/day for 14-17 kg; 50-75% of the standard dose). The therapeutic range established for efavirenz is 1000-4000 ng/ml.\n*Efavirenz in COMBINATION preparation: 1. Initiate the combination preparation and titrate the efavirenz dose to plasma concentration if needed (reduction to 400 or 200 mg/day) The therapeutic range established for efavirenz is 1000-4000 ng/ml."	0	0	1	CYP2B6	efavirenz	4346	1186
269	DPWG	PA166182846	"Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the *5/*6, *5/*18 or other CYP2B6 IM genotypes, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed."	*5/*6 or *5/*18	*5/*6; *5/*18	"Determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed. In 14 adults with a genotype with the same effect, a reduction of the dose to 400 mg/day (2/3 of the standard dose) was sufficient to achieve therapeutic plasma concentrations and for the side effects to reduce or disappear. The therapeutic range established for efavirenz is 1000-4000 ng/mL."	0	0	1	CYP2B6	efavirenz	4346	1186
270	CPIC	PA166181885	"The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy."	Ultrarapid Metabolizer		"Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml."	0	0	1	CYP2D6	atomoxetine	4352	413
271	CPIC	PA166181885	"The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy."	Normal Metabolizer		"Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days.  If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml."	0	0	1	CYP2D6	atomoxetine	4352	413
272	CPIC	PA166181885	"The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy."	Intermediate Metabolizer		"Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days.  If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml."	0	0	1	CYP2D6	atomoxetine	4352	413
273	CPIC	PA166181885	"The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy."	Normal Metabolizer + *10		"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing.  If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose."	0	0	1	CYP2D6	atomoxetine	4352	413
274	CPIC	PA166181885	"The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy."	Intermediate Metabolizer + *10		"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing.  If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose."	0	0	1	CYP2D6	atomoxetine	4352	413
275	CPIC	PA166181885	"The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy."	Intermediate Metabolizer		"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing.  If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose."	0	0	1	CYP2D6	atomoxetine	4352	413
276	CPIC	PA166181885	"The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy."	Poor Metabolizer		"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 h after dosing.  If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose."	0	0	1	CYP2D6	atomoxetine	4352	413
277	DPWG	PA166104969	Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.	Intermediate Metabolizer		"1. Indications other than diagnosis of Brugada syndrome: reduce the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.2.Provocation test for diagnosis of Brugada syndrome:No action required.At a dose of 2.0 mg/kg body weight to a maximum of 150 mg, the response is better for patients with alleles that result in reduced activity.All 5 patients with these alleles and 20% of the patients with two fully active alleles exhibited a response within 30 minutes."	0	0	1	CYP2D6	flecainide	4352	1368
278	DPWG	PA166104969	Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.	Poor Metabolizer		1. reduce the dose to 50% of the standard dose and record an ECG and monitor the plasma concentration.	0	0	1	CYP2D6	flecainide	4352	1368
279	DPWG	PA166104975	The Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.	Intermediate Metabolizer		"Do not exceed the following doses (75% of the standard maximum dose): adults < 65 years: 15 mg/day, adults 65 years or older: 7.5 mg/day"	0	0	1	CYP2C19	escitalopram	4349	1263
280	DPWG	PA166104975	The Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.	Poor Metabolizer		"Do not exceed the following doses (50% of the standard maximum dose): adults < 65 years: 10 mg/day, adults 65 years or older: 5 mg/day"	0	0	1	CYP2C19	escitalopram	4349	1263
281	CPIC	PA166124619	"The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments."	Ultrarapid Metabolizer		Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments	0	0	1	CYP3A5	tacrolimus	4368	3127
282	CPIC	PA166124619	"The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments."	Intermediate Metabolizer		Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments	0	0	1	CYP3A5	tacrolimus	4368	3127
283	DPWG	PA166184614	Select an alternative drug or reduce the initial dose of azathioprine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	Intermediate Metabolizer		"- IMMUNOSUPPRESSION:start with 50% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy.\nNote: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of < 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.\nNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\nNote: more stringent dose reductions are necessary if the patient is also TPMT IM or TPMT PM."	0	0	1	NUDT15	azathioprine	13756	432
284	DPWG	PA166184614	Select an alternative drug or reduce the initial dose of azathioprine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.	Poor Metabolizer		"Avoid azathioprine and mercaptopurine.  If it is not possible to avoid azathioprine and mercaptopurine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur. Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy.\nNote: The percentage of 10% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of < 20% was calculated for NUDT15 PM, but there were insufficient data available to calculate the exact percentage.\nNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants."	1	0	1	NUDT15	azathioprine	13756	432
285	DPWG	PA166184528	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.	Ultrarapid Metabolizer		"Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS: avoid clomipramine. Antidepressants that are not metabolised by CYP2C19 - or to a lesser extent - include, for example, fluoxetine, fluvoxamine and paroxetine. If it is not possible to avoid clomipramine: monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is greater than 200 ng/mL in combination with a plasma concentration of desmethylclomipramine that is as low as possible. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. A sum of the plasma concentrations of clomipramine and desmethylclomipramine exceeding 600 ng/mL is considered toxic. Add a low dose of fluvoxamine if necessary, to inhibit CYP2C19 and CYP1A2 and thereby inhibit the conversion of clomipramine to desmethylclomipramine. Indication DEPRESSION: no action required"	1	0	1	CYP2C19	clomipramine	4349	838
286	CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	Ultrarapid Metabolizer		Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	1	CYP2C19	dexlansoprazole	4349	1023
287	CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	Rapid Metabolizer		Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	0	CYP2C19	dexlansoprazole	4349	1023
288	CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	Normal Metabolizer		Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.	0	0	0	CYP2C19	dexlansoprazole	4349	1023
289	CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	Likely Intermediate Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	0	CYP2C19	dexlansoprazole	4349	1023
290	CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	Intermediate Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	0	CYP2C19	dexlansoprazole	4349	1023
291	CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	Likely Poor Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	0	CYP2C19	dexlansoprazole	4349	1023
292	CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	Poor Metabolizer		"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy."	0	0	0	CYP2C19	dexlansoprazole	4349	1023
293	CPIC	PA166161954	The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	Intermediate Metabolizer		Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype.  Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	ondansetron	4352	2273
294	CPIC	PA166161954	The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	Poor Metabolizer		Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype.  Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	ondansetron	4352	2273
295	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	0	0	1	CYP2D6	clomipramine	4352	838
296	CPIC	PA166161955	The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	Intermediate Metabolizer		Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype.  Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	tropisetron	4352	3349
297	CPIC	PA166161955	The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	Poor Metabolizer		Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype.  Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	tropisetron	4352	3349
298	DPWG	PA166104954	"CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose."	Poor Metabolizer		"Use 70% of the standard dose and monitor the effect and side effects or the imipramine and desipramine plasma concentrations to determine the maintenance dose, or, avoid imipramine. Antidepressants that are not or to a lesser extent metabolised by CYP2C19 include, for example, nortriptyline, fluvoxamine and mirtazapine."	1	0	1	CYP2C19	imipramine	4349	1648
299	DPWG	PA166104995	"For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, use smaller steps in dose titration and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug."	Intermediate Metabolizer		"If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1. use smaller steps in dose titration and/or prescribe no more than 50% of the standard dose. OTHER CASES: 1. no action required"	0	0	1	CYP2D6	metoprolol	4352	2052
300	DPWG	PA166104995	"For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, use smaller steps in dose titration and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug."	Poor Metabolizer		"If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1.use smaller steps in dose titration and/or prescribe no more than 25% of the standard dose. OTHER CASES: 1. no action required"	0	0	1	CYP2D6	metoprolol	4352	2052
301	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	Intermediate Metabolizer		"1. The loading dose does not need to be adjusted.\n2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\n3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur."	0	0	1	CYP2C9	phenytoin	4351	2604
302	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	Poor Metabolizer		"1. The loading dose does not need to be adjusted.\n2. For the other doses, use 40-50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\n3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur."	0	0	1	CYP2C9	phenytoin	4351	2604
303	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*1/*2	*1/*2	"1. The loading dose does not need to be adjusted.\n2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\n3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur."	0	0	1	CYP2C9	phenytoin	4351	2604
304	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*1/*3	*1/*3	"1. The loading dose does not need to be adjusted.\n2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\n3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur."	0	0	1	CYP2C9	phenytoin	4351	2604
305	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*2/*2	*2/*2	"1. The loading dose does not need to be adjusted.\n2. For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\n3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur."	0	0	1	CYP2C9	phenytoin	4351	2604
306	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*2/*3	*2/*3	"1. The loading dose does not need to be adjusted.\n2. For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\n3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur."	0	0	1	CYP2C9	phenytoin	4351	2604
307	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*3/*3	*3/*3	"1. The loading dose does not need to be adjusted.\n2. For the other doses, use 40% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\n3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur."	0	0	1	CYP2C9	phenytoin	4351	2604
308	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*1/*2	*1/*2	"Standard loading dose. Reduce maintenance dose by 25%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)"	0	0	1	CYP2C9	phenytoin	4351	2604
309	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*2/*2	*2/*2	"Standard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)"	0	0	1	CYP2C9	phenytoin	4351	2604
310	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*1/*3	*1/*3	"Standard loading dose. Reduce maintenance dose by 25%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)"	0	0	1	CYP2C9	phenytoin	4351	2604
311	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*2/*3	*2/*3	"Standard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)"	0	0	1	CYP2C9	phenytoin	4351	2604
312	DPWG	PA166104984	Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.	*3/*3	*3/*3	"Standard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)"	0	0	1	CYP2C9	phenytoin	4351	2604
313	DPWG	PA166104937	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.	Poor Metabolizer		Administer no more than 10 mg/day or 300 mg/month (68-75% of the standard maximum dose of aripiprazole).	0	0	1	CYP2D6	aripiprazole	4352	380
314	DPWG	PA166184527	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the standard dose of brexpiprazole for patients carrying poor metabolizer alleles of CYP2D6.	Poor Metabolizer		Use half of the standard dose.	0	0	1	CYP2D6	brexpiprazole	4352	578
315	CPIC	PA166262221	Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.	Decreased Function		"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy)."	0	0	1	SLCO1B1	atorvastatin	19487	414
316	CPIC	PA166262221	Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.	Possible Decreased Function		"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy)."	0	0	1	SLCO1B1	atorvastatin	19487	414
317	CPIC	PA166262221	Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.	Poor Function		"Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy)."	0	0	1	SLCO1B1	atorvastatin	19487	414
318	CPNDS	PA166159180	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT)."	rs2229774 AA; rs2229774 AG	rs2229774 AA; rs2229774 AG	"High risk patients - the following management options should be considered:\n1. Increase frequency of monitoring with serial yearly echocardiographic monitoring an follow-up as recommended by COG guidelines (Level A recommendation)\n2. Aggressive screening and management of cardiovascular risk factors including obesity, diabetes, hypertension, coronary artery idea, lipid disorders and peripheral vascular disease (Level A recommendation)\n3. Prescribe dexrazoxane (Level B recommendation)\n4. Use liposomal encapsulated anthracycline preparations (Level C recommendation)\n5. Use of continuous inclusion or slower inclusion rates (Level C recommendation)\n6. Use of less cardiotoxic types of anthracyclines (Level C recommendation)\n7. Use of other cardioprotective agents (Level C recommendation)\n8. Prescribe alternative chemotherapy regiments for certain tumor types where alternative regiments have been shown to be equally effective (Level C recommendation)"	0	1	1	RARG	daunorubicin	17111	984
319	CPNDS	PA166159180	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT)."	rs2229774 AA; rs2229774 AG	rs7853758 GG; rs7853758 AG	"High risk patients - the following management options should be considered:\n1. Increase frequency of monitoring with serial yearly echocardiographic monitoring an follow-up as recommended by COG guidelines (Level A recommendation)\n2. Aggressive screening and management of cardiovascular risk factors including obesity, diabetes, hypertension, coronary artery idea, lipid disorders and peripheral vascular disease (Level A recommendation)\n3. Prescribe dexrazoxane (Level B recommendation)\n4. Use liposomal encapsulated anthracycline preparations (Level C recommendation)\n5. Use of continuous inclusion or slower inclusion rates (Level C recommendation)\n6. Use of less cardiotoxic types of anthracyclines (Level C recommendation)\n7. Use of other cardioprotective agents (Level C recommendation)\n8. Prescribe alternative chemotherapy regiments for certain tumor types where alternative regiments have been shown to be equally effective (Level C recommendation)"	0	1	1	SLC28A3	daunorubicin	19269	984
320	CPNDS	PA166159180	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT)."	rs7853758 GG; rs7853758 AG	rs17863783 TT; rs17863783 GT	"High risk patients - the following management options should be considered:\n1. Increase frequency of monitoring with serial yearly echocardiographic monitoring an follow-up as recommended by COG guidelines (Level A recommendation)\n2. Aggressive screening and management of cardiovascular risk factors including obesity, diabetes, hypertension, coronary artery idea, lipid disorders and peripheral vascular disease (Level A recommendation)\n3. Prescribe dexrazoxane (Level B recommendation)\n4. Use liposomal encapsulated anthracycline preparations (Level C recommendation)\n5. Use of continuous inclusion or slower inclusion rates (Level C recommendation)\n6. Use of less cardiotoxic types of anthracyclines (Level C recommendation)\n7. Use of other cardioprotective agents (Level C recommendation)\n8. Prescribe alternative chemotherapy regiments for certain tumor types where alternative regiments have been shown to be equally effective (Level C recommendation)"	0	1	1	UGT1A6	daunorubicin	22978	984
321	CPNDS	PA166159180	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT)."	rs17863783 TT; rs17863783 GT	rs2229774 AA; rs2229774 AG	"High risk patients - the following management options should be considered:\n1. Increase frequency of monitoring with serial yearly echocardiographic monitoring an follow-up as recommended by COG guidelines (Level A recommendation)\n2. Aggressive screening and management of cardiovascular risk factors including obesity, diabetes, hypertension, coronary artery idea, lipid disorders and peripheral vascular disease (Level A recommendation)\n3. Prescribe dexrazoxane (Level B recommendation)\n4. Use liposomal encapsulated anthracycline preparations (Level C recommendation)\n5. Use of continuous inclusion or slower inclusion rates (Level C recommendation)\n6. Use of less cardiotoxic types of anthracyclines (Level C recommendation)\n7. Use of other cardioprotective agents (Level C recommendation)\n8. Prescribe alternative chemotherapy regiments for certain tumor types where alternative regiments have been shown to be equally effective (Level C recommendation)"	0	1	1	RARG	doxorubicin	17111	1127
322	CPNDS	PA166159180	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT)."	rs2229774 AA; rs2229774 AG	rs7853758 GG; rs7853758 AG	"High risk patients - the following management options should be considered:\n1. Increase frequency of monitoring with serial yearly echocardiographic monitoring an follow-up as recommended by COG guidelines (Level A recommendation)\n2. Aggressive screening and management of cardiovascular risk factors including obesity, diabetes, hypertension, coronary artery idea, lipid disorders and peripheral vascular disease (Level A recommendation)\n3. Prescribe dexrazoxane (Level B recommendation)\n4. Use liposomal encapsulated anthracycline preparations (Level C recommendation)\n5. Use of continuous inclusion or slower inclusion rates (Level C recommendation)\n6. Use of less cardiotoxic types of anthracyclines (Level C recommendation)\n7. Use of other cardioprotective agents (Level C recommendation)\n8. Prescribe alternative chemotherapy regiments for certain tumor types where alternative regiments have been shown to be equally effective (Level C recommendation)"	0	1	1	SLC28A3	doxorubicin	19269	1127
323	CPNDS	PA166159180	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT)."	rs7853758 GG; rs7853758 AG	rs17863783 TT; rs17863783 GT	"High risk patients - the following management options should be considered:\n1. Increase frequency of monitoring with serial yearly echocardiographic monitoring an follow-up as recommended by COG guidelines (Level A recommendation)\n2. Aggressive screening and management of cardiovascular risk factors including obesity, diabetes, hypertension, coronary artery idea, lipid disorders and peripheral vascular disease (Level A recommendation)\n3. Prescribe dexrazoxane (Level B recommendation)\n4. Use liposomal encapsulated anthracycline preparations (Level C recommendation)\n5. Use of continuous inclusion or slower inclusion rates (Level C recommendation)\n6. Use of less cardiotoxic types of anthracyclines (Level C recommendation)\n7. Use of other cardioprotective agents (Level C recommendation)\n8. Prescribe alternative chemotherapy regiments for certain tumor types where alternative regiments have been shown to be equally effective (Level C recommendation)"	0	1	1	UGT1A6	doxorubicin	22978	1127
324	CPIC	PA166104949	"The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823."	Poor Metabolizer		An alternative oral anticoagulant might be considered.	1	1	1	CYP2C9	warfarin	4351	3480
325	CPNDS	PA166170751	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for TPMT gene variants when prescribing cisplatin in pediatric cancer patients. They recommend testing for the TPMT alleles *2, *3A, *3B or *3C in all pediatric cancer patients due to the association of these alleles with an increased risk of cisplatin-induced ototoxicity."	Patients carrying nonfunctional TPMT variants	*2; *3A; *3B; *3C; *4; *11; *14; *15; *23; *29; *41	"1. Physicians are encouraged to consider the use of otoprotectants (i.e. amifostine, sodium thiosulfate) if the patient's tumour type is one for which otoprotectants may be effective to prevent cisplatin-induced ototoxicity without adversely affecting antitumour activity (level C - optional recommendation)\n2. Alternative treatments may be prescribed when they have demonstrated equal efficacy, manageable and acceptable toxicity, less ototoxicity, and are considered options within the current standards of care (level C - optional recommendation)\n3. Where appropriate, physicians are encouraged to increase monitoring in high-risk patients (level C - optional recommendation)\n4. High risk patients should be encouraged to receive more frequent follow-up audiometric hearing tests after treatment has ended (level C - optional recommendation)"	0	1	1	TPMT	cisplatin	22019	818
326	ACR	PA166104993	Testing for the HLA-B*58:01 allele before starting allopurinol treatment is conditionally recommended for patients of Southeast Asian or African American descent.	HLA-B*58:01 positive		"Those with HLA-B*5801 and of Korean descent with stage 3 or worse CKD (HLA-B*5801 allele frequency ~12%), or of Han Chinese or Thai extraction irrespective of renal function (HLA-B*5801 allele frequency ~6-8%), have been highlighted in the literature as prime examples of subjects at high risk for AHS, marked by HLA-B*5801 hazard ratios of several hundred. Such high-risk individuals were recommended to be prescribed an alternative to allopurinol if HLA-B*5801 positive."	0	1	1	HLA-B	allopurinol	8015	127
327	CPNDS	PA166117280	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-A*31:01 or HLA-B*15:02 genotype when prescribing carbamazepine (CBZ).  They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-A*31:01 or HLA-B*15:02 allele.	HLA-A*31:01 positive		"Genetic testing for HLA-A*31:01 [or] HLA-B*15:02 is recommended for all CBZ-naive patients before initiation of CBZ therapy. In patients who have previously taken CBZ for > 3 months without any adverse effects, and in whom reinitiation of CBZ is considered, genetic testing is NOT recommended. In patients who have previously taken CBZ for a shorter period, genetic testing should be considered.\nIn patients who are positive for HLA-B*15:02 or HLA-A*31:01, alternative medications should be used as first-line therapy. Consideration in the choice of alternative medications should be given to the possibility of cross-reactivity with structurally similar AEDs (oxcarbazepine, lamotrigine, phenytoin, phenobarbital, primidone)."	0	1	1	HLA-A	carbamazepine	8014	665
328	CPNDS	PA166117280	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-A*31:01 or HLA-B*15:02 genotype when prescribing carbamazepine (CBZ).  They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-A*31:01 or HLA-B*15:02 allele.	HLA-B*15:02 positive		"Genetic testing for HLA-A*31:01 [or] HLA-B*15:02 is recommended for all CBZ-naive patients before initiation of CBZ therapy. In patients who have previously taken CBZ for > 3 months without any adverse effects, and in whom reinitiation of CBZ is considered, genetic testing is NOT recommended. In patients who have previously taken CBZ for a shorter period, genetic testing should be considered.\nIn patients who are positive for HLA-B*15:02 or HLA-A*31:01, alternative medications should be used as first-line therapy. Consideration in the choice of alternative medications should be given to the possibility of cross-reactivity with structurally similar AEDs (oxcarbazepine, lamotrigine, phenytoin, phenobarbital, primidone)."	0	1	1	HLA-B	carbamazepine	8015	665
329	CPNDS	PA166122666	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of CYP2D6 genotype when prescribing codeine. They recommend that poor metabolizers of CYP2D6 should not receive codeine for pain relief, and ultrametabolizers of CYP2D6 should avoid codeine for pain relief."	Ultrarapid Metabolizer		"Ultrarapid metabolizers of CYP2D6 should avoid codeine for pain relief and receive alternative analgesics that do not have potent CYP2D6 metabolites (Grade B - moderate recommendation).\nCertain populations, especially opioid na�ve breastfed neonates of mothers with functional CYP2D6 gene duplications taking codeine and young children may be particularly susceptible to codeine-induced central nervous system depression. Breastfeeding mothers and young children who are ultrarapid metabolizers of CYP2D6 should avoid codeine (Grade A - strong recommendation)."	1	1	1	CYP2D6	codeine	4352	854
330	CPIC	PA166105008	"The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE)."	HLA-A*31:01 positive + HLA-B*15:02 negative		"A. If patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine.\nB. If patient is carbamazepine-naive and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.\nC. The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within 3 months of regular dosing. Therefore, if patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine."	0	1	1	HLA-A	carbamazepine	8014	665
331	CPIC	PA166105008	"The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE)."	HLA-A*31:01 positive + HLA-B*15:02 negative		"A. If patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine.\nB. If patient is carbamazepine-naive and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.\nC. The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within 3 months of regular dosing. Therefore, if patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine."	0	1	1	HLA-B	carbamazepine	8015	665
332	DPWG	PA166104989	"The Dutch Pharmacogenetics Working Group Guideline for atomoxetine states for CYP2D6 ultrarapid metabolizers, to be alert to reduced efficacy of atomoxetine or select an alternative drug as a precaution.  Be alert to ADEs in CYP2D6 poor metabolizers."	Ultrarapid Metabolizer		1. Be extra alert to reduced efficacy of the treatment.\n2. Advise the patient to contact their doctor in the event of inadequate effect.\n3. An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.	0	1	0	CYP2D6	atomoxetine	4352	413
333	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Poor Metabolizer		Contraindicated treatment with fluoropyrimidines; look for alternative agents*	0	1	0	DPYD	capecitabine	5039	655
334	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Poor Metabolizer		Contraindicated treatment with fluoropyrimidines; look for alternative agents*	0	1	0	DPYD	fluorouracil	5039	1390
335	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Poor Metabolizer		Contraindicated treatment with fluoropyrimidines; look for alternative agents*	0	1	0	DPYD	tegafur	5039	3158
336	DPWG	PA166182844	"Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms."	SLCO1B1 521 CC	rs4149056 CC	"1. Choose an alternative.\nConsider any additional risk factors for statin-induced myopathy.\nAtorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patients with additional risk factors for statin-induced myopathy.\nRosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.\nFluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors."	0	1	0	SLCO1B1	simvastatin	19487	2979
337	CPIC	PA166127638	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19."	Ultrarapid Metabolizer		Consider an alternative drug not predominantly metabolized by CYP2C19.	0	1	0	CYP2C19	citalopram	4349	819
338	CPIC	PA166127638	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19."	Ultrarapid Metabolizer		Consider an alternative drug not predominantly metabolized by CYP2C19.	0	1	0	CYP2C19	escitalopram	4349	1263
339	DPWG	PA166104962	"Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor propafenone plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers."	Ultrarapid Metabolizer		"It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.\n1. Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.\n2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone."	0	1	0	CYP2D6	propafenone	4352	2730
340	DPWG	PA166104962	"Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor propafenone plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers."	Intermediate Metabolizer		"It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.\n1. Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects\n2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone."	0	1	0	CYP2D6	propafenone	4352	2730
341	DPWG	PA166265341	"Avoid lamotrigine in patients with HLA-B*1502 if an alternative is available. If avoidance is not possible, advise to report any rash immediately."	HLA-B*15:02 positive		"Carefully weigh the risk of SJS/TEN against the benefits.\nAvoid lamotrigine if an alternative is available. Carbamazepine carries a much higher risk of SJS/TEN in these patients and is therefore not an alternative. A similar risk has been reported for phenytoin as for lamotrigine. The same applies to oxcarbazepine, but the most severe forms (SJS/TEN overlap and TEN) have not been observed with oxcarbazepine.\nIf it is not possible to avoid this medication, then advise the patient to report any skin rash immediately"	1	1	0	HLA-B	lamotrigine	8015	1789
342	CPIC	PA166127639	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.	Ultrarapid Metabolizer		"Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19."	0	0	0	CYP2C19	sertraline	4349	2963
343	CPIC	PA166192321	The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Intermediate Metabolizer		Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).	0	1	0	CYP2C9	piroxicam	4351	2638
344	CPIC	PA166192321	The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Poor Metabolizer		Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).	0	1	0	CYP2C9	piroxicam	4351	2638
345	DPWG	PA166264881	Phenytoin should be avoided if possible in patients with the HLA-B*15:02 allele.	HLA-B*15:02 positive		"Carefully weigh the risk of SJS/TEN against the benefits.\nAvoid phenytoin if an alternative is possible. Carbamazepine carries a 10-fold higher risk of SJS/TEN for these patients and is therefore not an alternative. A comparable risk has been reported for lamotrigine as for phenytoin. The same applies for oxcarbazepine, but the most severe forms (SJS/TEN overlap and TEN) are not observed with oxcarbazepine.\nIf it is not possible to avoid this medication, then advise the patient to report any skin rash immediately"	1	1	0	HLA-B	phenytoin	8015	2604
346	CPIC	PA166119846	"Rasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The G6PD gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence."	Deficient; Deficient with CNSHA		Rasburicase is contraindicated; alternatives include allopurinol.	0	1	0	G6PD	rasburicase	6821	2819
347	CPIC	PA166119846	"Rasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The G6PD gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence."	Variable		"To ascertain that G6PD status is normal, enzyme activity must be measured; alternatives include allopurinol."	0	1	0	G6PD	rasburicase	6821	2819
348	DPWG	PA166265162	Consider an alternative drug to carbamazepine in patients with the HLA-B*1502 0r HLA-B*1511 alleles.	HLA-B*15:02 positive		"1. choose an alternative if possible Phenytoin, lamotrigine and oxcarbazepine also pose an increased risk of SJS/TEN in these patients, but the final risk is 10-fold lower for these medicines than for carbamazepine. Furthermore, in the case of oxcarbazepine, the most severe forms (SJS/TEN overlap and TEN) have not been observed."	0	1	0	HLA-B	carbamazepine	8015	665
349	DPWG	PA166265162	Consider an alternative drug to carbamazepine in patients with the HLA-B*1502 0r HLA-B*1511 alleles.	HLA-B*15:11 positive		"1. carefully weigh the risk of SJS/TEN against the benefits 2. if an alternative is an option, choose an alternative"	0	1	0	HLA-B	carbamazepine	8015	665
350	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	CACNA1S	desflurane	2292	1004
351	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	CACNA1S	enflurane	2292	1220
352	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	CACNA1S	halothane	2292	1544
353	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	CACNA1S	isoflurane	2292	1740
354	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	CACNA1S	methoxyflurane	2292	2026
355	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	CACNA1S	sevoflurane	2292	2966
356	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	CACNA1S	succinylcholine	2292	3060
357	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	RYR1	desflurane	18364	1004
358	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	RYR1	enflurane	18364	1220
359	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	RYR1	halothane	18364	1544
360	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	RYR1	isoflurane	18364	1740
361	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	RYR1	methoxyflurane	18364	2026
362	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	RYR1	sevoflurane	18364	2966
363	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Malignant Hyperthermia Susceptibility		"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS."	0	1	0	RYR1	succinylcholine	18364	3060
364	CPIC	PA166262241	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Poor Function		Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins).	0	1	1	SLCO1B1	lovastatin	19487	1894
365	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	increased risk of aminoglycoside-induced hearing loss		Avoid aminoglycoside antibiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	1	1	0	MT-RNR1	amikacin	12748	173
366	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	increased risk of aminoglycoside-induced hearing loss		Avoid aminoglycoside antibiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	1	1	0	MT-RNR1	gentamicin	12748	1476
367	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	increased risk of aminoglycoside-induced hearing loss		Avoid aminoglycoside antibiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	1	1	0	MT-RNR1	kanamycin	12748	1768
368	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	increased risk of aminoglycoside-induced hearing loss		Avoid aminoglycoside antibiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	1	1	0	MT-RNR1	paromomycin	12748	2519
369	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	increased risk of aminoglycoside-induced hearing loss		Avoid aminoglycoside antibiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	1	1	0	MT-RNR1	plazomicin	12748	2651
370	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	increased risk of aminoglycoside-induced hearing loss		Avoid aminoglycoside antibiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	1	1	0	MT-RNR1	streptomycin	12748	3052
371	CPIC	PA166229081	Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL).	increased risk of aminoglycoside-induced hearing loss		Avoid aminoglycoside antibiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	1	1	0	MT-RNR1	tobramycin	12748	3278
372	DPWG	PA166265201	Oxcarbazepine should be avoided if an alternative is available in patients with the HLA-B*15:02 allele.	HLA-B*15:02 positive		"Carefully weigh the risk of SJS/TEN against the benefits.\nAvoid oxcarbazepine if an alternative is available. Carbamazepine carries a 10-fold higher risk of SJS/TEN in these patients and is therefore not an alternative. In these patients, phenytoin and lamotrigine carry a similar risk of SJS/TEN as oxcarbazepine, but more severe forms of SJS/TEN (SJS/TEN overlap and TEN) are also observed with these medicines. Therefore, they are also not suitable as alternatives.\nIf it is not possible to avoid oxcarbazepine, advise the patient to report any rash immediately."	1	1	0	HLA-B	oxcarbazepine	8015	2468
373	DPWG	PA166104955	"In individuals who carry the Factor V Leiden allele (rs6025 T) and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used."	Factor V Leiden heterozygous	rs6025 TT	"If the patient has a FAMILY HISTORY WITH A LOT OF THROMBOSIS, or has had a PREVIOUS THROMBOSIS:\n1. Advise the prescriber to avoid the use of contraceptives that contain oestrogens and prescribe a non-hormone contraceptive-such as a copper IUD - as an alternative. One could also opt for a progestogen-only contraceptive method, such as the depot injection, an IUD with levonorgestrel or an implant with etonogestrel.\n- OTHER CASES:\n1. Advise the patient to avoid additional risk factors for thrombosis (obesity, smoking, etc.)."	1	1	0	F5	hormonal contraceptives for systemic use	5820	1576
374	DPWG	PA166104955	"In individuals who carry the Factor V Leiden allele (rs6025 T) and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used."	Factor V Leiden homozygous	rs6025 CT	"If the patient has a FAMILY HISTORY WITH A LOT OF THROMBOSIS, or has had a PREVIOUS THROMBOSIS:\n1. Advise the prescriber to avoid the use of contraceptives that contain oestrogens and prescribe a non-hormone contraceptive-such as a copper IUD - as an alternative. One could also opt for a progestogen-only contraceptive method, such as the depot injection, an IUD with levonorgestrel or an implant with etonogestrel.\n- OTHER CASES:\n1. Advise the patient to avoid additional risk factors for thrombosis (obesity, smoking, etc.)."	1	1	0	F5	hormonal contraceptives for systemic use	5820	1576
375	CPIC	PA166105005	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Poor Function		Prescribe an alternative statin depending on the desired potency (see Figure 1 for recommendations for alternative statins).	0	1	1	SLCO1B1	simvastatin	19487	2979
376	DPWG	PA166104968	"For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine."	Intermediate Metabolizer		"It is not possible to offer adequately substantiated advice for dose reduction based on the literature.\n1. Choose an alternative. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\n2. If an alternative is not an option and side effects occur:\na. reduce the dose\nb. check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum."	0	1	0	CYP2D6	venlafaxine	4352	3423
377	DPWG	PA166104968	"For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine."	Poor Metabolizer		"It is not possible to offer adequately substantiated advice for dose reduction based on the literature.\n1. Choose an alternative. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\n2. If an alternative is not an option and side effects occur:\na. reduce the dose\nb. check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum. Furthermore, a reduced effectiveness of venlafaxine has been observed in depression patients with this genetic polymorphism."	0	1	0	CYP2D6	venlafaxine	4352	3423
378	DPWG	PA166104959	"Be alert to a reduced efficacy of tramadol in CYP2D6 intermediate or poor metabolizers. If tramadol is not effective in these patients, try a dose increase or select an alternative to tramadol (not codeine) and be alert for symptoms of insufficient pain relief. For CYP2D6 ultrarapid metabolizers, use an alternative to tramadol (not codeine) or use 40% of the standard dose and be alert to side effects."	Intermediate Metabolizer		"It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.\n1. be alert to a reduced effectiveness\n2. in the case of inadequate effectiveness:\na. try a dose increase\nb. if this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.\n3. if no alternative is selected: advise the patient to report inadequate analgesia"	0	1	0	CYP2D6	tramadol	4352	3302
379	DPWG	PA166104959	"Be alert to a reduced efficacy of tramadol in CYP2D6 intermediate or poor metabolizers. If tramadol is not effective in these patients, try a dose increase or select an alternative to tramadol (not codeine) and be alert for symptoms of insufficient pain relief. For CYP2D6 ultrarapid metabolizers, use an alternative to tramadol (not codeine) or use 40% of the standard dose and be alert to side effects."	Poor Metabolizer		"It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.\n1. be alert to a reduced effectiveness\n2. in the case of inadequate effectiveness:\na. try a dose increase.\nb. if this does not work: choose an alternative Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.\n3. if no alternative is selected: advise the patient to report inadequate analgesia."	0	1	0	CYP2D6	tramadol	4352	3302
380	DPWG	PA166182823	"The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CYP3A inducers."	Ultrarapid Metabolizer		Eliglustat is contra-indicated. Choose an alternative if possible.	0	1	0	CYP2D6	eliglustat	4352	1202
381	DPWG	PA166265161	Consider an alternative drug to carbamazepine in patients with the HLA-A*3101 allele.	HLA-A*31:01 positive		"1. carefully weigh the risk of DRESS and SJS/TEN against the benefits 2. if an alternative is an option, choose an alternative"	0	1	0	HLA-A	carbamazepine	8014	665
382	CPIC	PA166192301	"The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Poor Metabolizer		Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).	0	1	0	CYP2C9	meloxicam	4351	1977
383	CPIC	PA166161537	"The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations."	Ultrarapid Metabolizer		"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole."	0	1	0	CYP2C19	voriconazole	4349	3473
384	CPIC	PA166161537	"The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations."	Rapid Metabolizer		"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole."	0	1	0	CYP2C19	voriconazole	4349	3473
385	CPIC	PA166161537	"The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations."	Poor Metabolizer		"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring."	0	1	1	CYP2C19	voriconazole	4349	3473
386	DPWG	PA166182810	"Monitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*5701."	HLA-B*57:01 positive		1. Regularly monitor the patient’s liver function\n2. Choose an alternative if liver enzymes and/or bilirubin levels are elevated	0	1	0	HLA-B	flucloxacillin	8015	1371
387	CPIC	PA166127636	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response."	Ultrarapid Metabolizer		Select alternative drug not predominantly metabolized by CYP2D6.	0	1	0	CYP2D6	paroxetine	4352	2520
388	DPWG	PA166104969	Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.	Ultrarapid Metabolizer		"There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone."	0	1	0	CYP2D6	flecainide	4352	1368
389	CPIC	PA166161954	The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	Ultrarapid Metabolizer		Select and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron).	0	1	0	CYP2D6	ondansetron	4352	2273
390	CPIC	PA166128738	"The CPIC dosing guideline recommends considering advising individuals who carry two decreased function UGT1A1 alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function UGT1A1 alleles, respectively."	Poor Metabolizer		Consider an alternative agent particularly where jaundice would be of concern to the patient.	0	1	0	UGT1A1	atazanavir	22969	408
391	DPWG	PA166104956	"Avoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers."	Poor Metabolizer		"PERCUTANEOUS CORONARY INTERVENTION, STROKE or TIA: avoid clopidogrel. Prasugrel, ticagrelor and acetylsalicylic acid/dipyridamole are not metabolised by CYP2C19 (or to a lesser extent).\nOTHER INDICATIONS: determine the level of inhibition of platelet aggregation by clopidogrel. Consider an alternative in poor responders. Prasugrel and ticagrelor are not metabolised by CYP2C19 (or to a lesser extent)."	1	1	0	CYP2C19	clopidogrel	4349	842
392	CPIC	PA166161955	The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	Ultrarapid Metabolizer		Select and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron).	0	1	0	CYP2D6	tropisetron	4352	3349
393	CPIC	PA166192341	The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Intermediate Metabolizer		Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).	0	1	0	CYP2C9	tenoxicam	4351	3177
394	CPIC	PA166192341	The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Poor Metabolizer		Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).	0	1	0	CYP2C9	tenoxicam	4351	3177
395	RNPGx	PA166202481	"Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day."	*3/*3	*3/*3	"Based on TDM, 0.15 mg/kg/day."	0	0	0	CYP3A5	tacrolimus	4368	3127
396	CPNDS	PA166170752	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for variants in VKORC1 and CYP2C9 in adult and pediatric patients with an indication for warfarin. They recommend testing for the VKORC1 SNP -1639G>A (rs9923231) and the CYP2C9 alleles *2 and *3 in order to better guide warfarin dosage.	*1; *2; *3	*1; *2; *3	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for variants in VKORC1 and CYP2C9 in adult and pediatric patients with an indication for warfarin. They recommend testing for the VKORC1 SNP -1639G>A (rs9923231) and the CYP2C9 alleles *2 and *3 in order to better guide warfarin dosage.	0	0	1	CYP2C9	warfarin	4351	3480
397	RNPGx	PA166202501	"Testing for the main CYP2C19 deficiency alleles before instituting clopidogrel treatment is recommended (a test is essential for coronary angioplasty with stenting and based on the current state of knowledge this test is potentially useful in the other indications). For patients carrying at least one deficiency allele, the RNPGx recommends using an alternative treatment that is not a CYP2C19 substrate (eg. prasugrel, ticagrelor)."	*17	*17	"Although the presence of the CYP2C19*17 allele, whether in a heterozygous or homozygous state, has been associated with increased hemorrhagic risk in patients treated with clopidogrel, it appears to favor the drug�s efficacy, reducing the incidence of recurrent thromboembolic events. Consequently, considering current knowledge, there is no guideline concerning the appropriate dosage to prescribe for a patient with the *17 allele."	0	0	1	CYP2C19	clopidogrel	4349	842
398	CPNDS	PA166122666	"The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of CYP2D6 genotype when prescribing codeine. They recommend that poor metabolizers of CYP2D6 should not receive codeine for pain relief, and ultrametabolizers of CYP2D6 should avoid codeine for pain relief."	Poor Metabolizer		Poor metabolizers of CYP2D6 should not receive codeine for pain relief (Grade A - strong recommendation).	0	1	0	CYP2D6	codeine	4352	854
399	CFF	PA166178241	"Ivacaftor is suggested for some cystic fibrosis patients with specific CFTR gating mutations, including the R117H or G551D variants."	rs78655421; rs75527207	rs78655421; rs75527207	"For adults and children aged 6 years and older with CF due to gating mutations other than G551D or R117H, the guideline panel made a conditional recommendation for treatment with IVA (ivacaftor).\nFor those with the R117H mutation, the guideline panel made a conditional recommendation for treatment with IVA for 1) adults aged 18 years or older, and 2) children aged 6�17 years with a forced expiratory volume in 1 second (FEV1) less than 90% predicted.\nFor those with the R117H mutation, the guideline panel made a conditional recommendation against treatment with IVA for 1) children aged 12�17 years with an FEV1 greater than 90% predicted, and 2) children less than 6 years of age."	0	0	0	CFTR	ivacaftor	3250	1759
400	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 positive		"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.\nOptional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing."	1	1	0	HLA-B	fosphenytoin	8015	1430
401	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 positive		"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.\nOptional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing."	1	1	0	HLA-B	phenytoin	8015	2604
402	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Normal Metabolizer		"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	0	0	0	HLA-B	fosphenytoin	8015	1430
403	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Normal Metabolizer		"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	0	0	0	HLA-B	phenytoin	8015	2604
404	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Intermediate Metabolizer		"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	0	0	0	HLA-B	fosphenytoin	8015	1430
405	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Intermediate Metabolizer		"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	0	0	0	HLA-B	phenytoin	8015	2604
406	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + Indeterminate		No recommendation	0	0	0	HLA-B	fosphenytoin	8015	1430
407	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + Indeterminate		No recommendation	0	0	0	HLA-B	phenytoin	8015	2604
408	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Normal Metabolizer		"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	0	0	0	CYP2C9	fosphenytoin	4351	1430
409	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Normal Metabolizer		"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	0	0	0	CYP2C9	phenytoin	4351	2604
410	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Intermediate Metabolizer		"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	0	0	0	CYP2C9	fosphenytoin	4351	1430
411	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + CYP2C9 Intermediate Metabolizer		"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice."	0	0	0	CYP2C9	phenytoin	4351	2604
412	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + Indeterminate		No recommendation	0	0	0	CYP2C9	fosphenytoin	4351	1430
413	CPIC	PA166122806	"Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (""HLA-B*15:02-positive"") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin."	HLA-B*15:02 negative + Indeterminate		No recommendation	0	0	0	CYP2C9	phenytoin	4351	2604
414	CPIC	PA166105008	"The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE)."	HLA-A*31:01 negative + HLA-B*15:02 negative		Use carbamazepine per standard dosing guidelines.	0	0	0	HLA-A	carbamazepine	8014	665
415	CPIC	PA166105008	"The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE)."	HLA-A*31:01 negative + HLA-B*15:02 positive		"A. If patient is carbamazepine-naive, do not use carbamazepine.\nB. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherance to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future."	0	0	0	HLA-A	carbamazepine	8014	665
416	CPIC	PA166105008	"The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE)."	HLA-A*31:01 negative + HLA-B*15:02 negative		Use carbamazepine per standard dosing guidelines.	0	0	0	HLA-B	carbamazepine	8015	665
417	CPIC	PA166105008	"The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either HLA-B*15:02 or HLA-A*31:01 due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, HLA-A*31:01 is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE)."	HLA-A*31:01 negative + HLA-B*15:02 positive		"A. If patient is carbamazepine-naive, do not use carbamazepine.\nB. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherance to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future."	0	0	0	HLA-B	carbamazepine	8015	665
418	DPWG	PA166104989	"The Dutch Pharmacogenetics Working Group Guideline for atomoxetine states for CYP2D6 ultrarapid metabolizers, to be alert to reduced efficacy of atomoxetine or select an alternative drug as a precaution.  Be alert to ADEs in CYP2D6 poor metabolizers."	Poor Metabolizer		"1. Start with the normal initial dose, bearing in mind that an increase in this dose probably will not be required.\n2. Advise the patient to seek contact if side effects occur (such as decreased appetite, vomiting, abdominal pain, constipation, insomnia, early waking, drowsiness, irritability, pupil dilation and itching).\n3. If the medicine is effective, but side effects occur: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 8-11 times higher for PM than for EM at the same dose."	0	0	0	CYP2D6	atomoxetine	4352	413
419	CPIC	PA166122686	"The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction."	Normal Metabolizer		"Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration"	0	0	0	DPYD	fluorouracil	5039	1390
420	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Normal Metabolizer		According to the data sheet	0	0	0	DPYD	capecitabine	5039	655
421	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Normal Metabolizer		According to the data sheet	0	0	0	DPYD	fluorouracil	5039	1390
422	SEFF	PA166254881	"Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose."	Normal Metabolizer		According to the data sheet	0	0	0	DPYD	tegafur	5039	3158
423	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Normal Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	1	1	SLCO1B1	rosuvastatin	19487	2890
424	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Increased Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	1	1	SLCO1B1	rosuvastatin	19487	2890
425	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Decreased Function		Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	0	1	1	SLCO1B1	rosuvastatin	19487	2890
426	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Possible Decreased Function		Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	0	1	1	SLCO1B1	rosuvastatin	19487	2890
427	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Indeterminate		No recommendation.	0	1	1	SLCO1B1	rosuvastatin	19487	2890
428	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Normal Function		Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	0	1	1	ABCG2	rosuvastatin	83	2890
429	CPIC	PA166262321	"Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose."	Decreased Function		Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines.	0	1	1	ABCG2	rosuvastatin	83	2890
430	DPWG	PA166104991	"Avoid abacavir for patients who have the HLA-B*57:01 allele (patients who are ""HLA-B*57:01-positive"")."	HLA-B*57:01 positive		Abacavir is contra-indicated for HLA-B*5701-positive patients.\n1. Avoid abacavir.	1	0	0	HLA-B	abacavir	8015	26
431	CPIC	PA166114461	"Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain CFTR variants.  See full guideline for disclaimers, further details and supporting evidence."	"Homozygous or Heterozygous G551D-CFTR, rs75527207 genotype AA or AG"	rs75527207 AA; rs75527207 AG	Use ivacaftor according to the product label	0	0	0	CFTR	ivacaftor	3250	1759
432	CPIC	PA166114461	"Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain CFTR variants.  See full guideline for disclaimers, further details and supporting evidence."	"Homozygous for F508del-CFTR, rs113993960 or rs199826652 genotype del/del"	rs113993960 del/del; rs199826652 del/del	Ivacaftor is not recommended	0	0	0	CFTR	ivacaftor	3250	1759
433	CPIC	PA166114461	"Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain CFTR variants.  See full guideline for disclaimers, further details and supporting evidence."	"Homozygous or heterozygous for one of the following CFTR variants: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, G1349D, 2789+5G->A, 3272-26A->G, 3849+10kbC->T, 711+1G->T and E831X"	E56K; P67L; R74W; D110E; D110H; R117C; R117H; G178R; E193K; L206W; R347H; R352Q; A455E; S549N; S549R(A>C); S549R(T>G); G551D; G551S; D579G; S945L; S977F; F1052V; K1060T; A1067T; G1069R; R1070Q; R1070W; F1074L; D1152H; G1244E; S1251N; S1255P; D1270N; G1349D; 2789+5G->A; 3272-26A->G; 3849+10kbC->T; 711+3A->G; E831X	Use ivacaftor according to the product label	0	0	0	CFTR	ivacaftor	3250	1759
434	DPWG	PA166222801	The Dutch Pharmacogenetics Working Group Guideline for flucytosine states that patients with a DPYD activity score of 0 should avoid flucytosine. Patients with a DPYD activity score of 1 or 1.5 should be alert to the occurrence of severe side effects and flucytosine should be stopped if severe side effects occur.	DPD AS 0	AS 0	Avoid flucytosine	1	0	0	DPYD	flucytosine	5039	1373
435	DPWG	PA166222801	The Dutch Pharmacogenetics Working Group Guideline for flucytosine states that patients with a DPYD activity score of 0 should avoid flucytosine. Patients with a DPYD activity score of 1 or 1.5 should be alert to the occurrence of severe side effects and flucytosine should be stopped if severe side effects occur.	DPD AS 1	AS 1	"Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea. In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur."	0	0	0	DPYD	flucytosine	5039	1373
436	DPWG	PA166222801	The Dutch Pharmacogenetics Working Group Guideline for flucytosine states that patients with a DPYD activity score of 0 should avoid flucytosine. Patients with a DPYD activity score of 1 or 1.5 should be alert to the occurrence of severe side effects and flucytosine should be stopped if severe side effects occur.	DPD AS 1.5	AS 1.5	"Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea. In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur."	0	0	0	DPYD	flucytosine	5039	1373
437	CPIC	PA166176623	The CPIC Dosing Guideline for oxcarbazepine recommends an alternative drug for oxcarbazepine-naive patients carrying at least one copy of HLA-B*15:02 due to the association of this allele with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).	HLA-B*15:02 negative		Use oxcarbazepine per standard dosing guidelines.	0	0	0	HLA-B	oxcarbazepine	8015	2468
438	CPIC	PA166176623	The CPIC Dosing Guideline for oxcarbazepine recommends an alternative drug for oxcarbazepine-naive patients carrying at least one copy of HLA-B*15:02 due to the association of this allele with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).	HLA-B*15:02 positive		"A. If patient is oxcarbazepine-naive, do not use oxcarbazepine.\nB. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherance to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future."	0	0	0	HLA-B	oxcarbazepine	8015	2468
439	CPIC	PA166105002	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	desipramine	4352	1005
440	DPWG	PA166182819	Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.	Ultrarapid Metabolizer		NO action is required for this gene-drug interaction.	0	0	0	CYP2D6	pimozide	4352	2619
441	CPIC	PA166104996	Alternate non-tramadol analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of codeine is warranted for CYP2D6 normal and intermediate metabolizers.	Ultrarapid Metabolizer		"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid."	1	0	0	CYP2D6	codeine	4352	854
442	CPIC	PA166104996	Alternate non-tramadol analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of codeine is warranted for CYP2D6 normal and intermediate metabolizers.	Normal Metabolizer		Use codeine label recommended age- or weight-specific dosing	0	0	0	CYP2D6	codeine	4352	854
443	CPIC	PA166104996	Alternate non-tramadol analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of codeine is warranted for CYP2D6 normal and intermediate metabolizers.	Intermediate Metabolizer		"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid"	0	0	0	CYP2D6	codeine	4352	854
444	CPIC	PA166104996	Alternate non-tramadol analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of codeine is warranted for CYP2D6 normal and intermediate metabolizers.	Poor Metabolizer		"Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid."	1	0	0	CYP2D6	codeine	4352	854
445	CPIC	PA166104996	Alternate non-tramadol analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of codeine is warranted for CYP2D6 normal and intermediate metabolizers.	Indeterminate		No recommendation	0	0	0	CYP2D6	codeine	4352	854
446	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	doxepin	4352	1126
447	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	doxepin	4349	1126
448	CPIC	PA166105000	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	doxepin	4349	1126
449	CPIC	PA166127638	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19."	Extensive Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	citalopram	4349	819
450	CPIC	PA166127638	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19."	Extensive Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	escitalopram	4349	1263
451	CPIC	PA166127638	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19."	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	citalopram	4349	819
452	CPIC	PA166127638	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19."	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	escitalopram	4349	1263
453	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	trimipramine	4352	3339
454	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	trimipramine	4349	3339
455	CPIC	PA166105001	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	trimipramine	4349	3339
456	CPIC	PA166105003	"Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (""HLA-B*58:01-positive"") due to significantly increased risk of allopurinol-induced SCAR."	HLA-B*58:01 negative		Use allopurinol per standard dosing guidelines	0	0	0	HLA-B	allopurinol	8015	127
457	CPIC	PA166105003	"Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (""HLA-B*58:01-positive"") due to significantly increased risk of allopurinol-induced SCAR."	HLA-B*58:01 positive		Allopurinol is contraindicated	0	0	0	HLA-B	allopurinol	8015	127
458	CPIC	PA166127639	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.	Extensive Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	sertraline	4349	2963
459	CPIC	PA166127639	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	sertraline	4349	2963
460	CPIC	PA166104997	"In individuals with the HLA-B*57:01 variant allele (""HLA-B*57:01-positive""), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence."	HLA-B*57:01 negative		Use abacavir per standard dosing guidelines	0	0	0	HLA-B	abacavir	8015	26
461	CPIC	PA166104997	"In individuals with the HLA-B*57:01 variant allele (""HLA-B*57:01-positive""), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence."	HLA-B*57:01 positive		Abacavir is not recommended	0	0	0	HLA-B	abacavir	8015	26
462	DPWG	PA166211021	"The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype."	*1/*2	*1/*2	NO action is required for this gene-drug interaction.	0	0	0	CYP2C9	siponimod	4351	2982
463	DPWG	PA166211021	"The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype."	*2/*2	*2/*2	NO action is required for this gene-drug interaction.	0	0	0	CYP2C9	siponimod	4351	2982
464	DPWG	PA166211021	"The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype."	*3/*3	*3/*3	Avoid siponimod.	1	0	0	CYP2C9	siponimod	4351	2982
465	DPWG	PA166211021	"The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype."	Poor Metabolizer		Avoid siponimod.	1	0	0	CYP2C9	siponimod	4351	2982
466	CPIC	PA166192321	The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Normal Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	piroxicam	4351	2638
467	CPIC	PA166192321	The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Intermediate Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	piroxicam	4351	2638
468	CPIC	PA166192321	The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Indeterminate		No recommendation.	0	0	0	CYP2C9	piroxicam	4351	2638
469	CPIC	PA166228121	"CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered."	Ultrarapid Metabolizer		No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	0	0	0	CYP2D6	hydrocodone	4352	1589
470	CPIC	PA166228121	"CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered."	Normal Metabolizer		Use hydrocodone label recommended age- or weight-specific dosing	0	0	0	CYP2D6	hydrocodone	4352	1589
471	CPIC	PA166228121	"CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered."	Intermediate Metabolizer		"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid"	0	0	0	CYP2D6	hydrocodone	4352	1589
472	CPIC	PA166228121	"CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered."	Poor Metabolizer		"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid"	0	0	0	CYP2D6	hydrocodone	4352	1589
473	CPIC	PA166228121	"CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered."	Indeterminate		No recommendation	0	0	0	CYP2D6	hydrocodone	4352	1589
474	CPIC	PA166228101	Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.	Ultrarapid Metabolizer		"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid."	1	0	0	CYP2D6	tramadol	4352	3302
475	CPIC	PA166228101	Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.	Normal Metabolizer		Use tramadol label recommended age- or weight-specific dosing	0	0	0	CYP2D6	tramadol	4352	3302
476	CPIC	PA166228101	Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.	Intermediate Metabolizer		"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-codeine opioid"	0	0	0	CYP2D6	tramadol	4352	3302
477	CPIC	PA166228101	Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.	Poor Metabolizer		"Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid."	1	0	0	CYP2D6	tramadol	4352	3302
478	CPIC	PA166228101	Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.	Indeterminate		No recommendation	0	0	0	CYP2D6	tramadol	4352	3302
479	DPWG	PA166104988	The recommendation for CYP2D6 poor metabolizers is to use 60% of the standard dose of haloperidol and for CYP2D6 ultrarapid metabolizers to use 1.5 times the standard dose or to choose an alternative to haloperidol.	Intermediate Metabolizer		NO action is required for this gene-drug interaction.	0	0	0	CYP2D6	haloperidol	4352	1542
480	DPWG	PA166104988	The recommendation for CYP2D6 poor metabolizers is to use 60% of the standard dose of haloperidol and for CYP2D6 ultrarapid metabolizers to use 1.5 times the standard dose or to choose an alternative to haloperidol.	Poor Metabolizer		Use 60% of the standard.	0	0	0	CYP2D6	haloperidol	4352	1542
481	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Indeterminate		None	0	0	0	TPMT	mercaptopurine	22019	1994
482	CPIC	PA166104945	Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Indeterminate		None	0	0	0	NUDT15	mercaptopurine	13756	1994
483	DPWG	PA166104939	"An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as ""essential"" and recommend DPYD testing prior to initiating fluoropyrimidines."	Activity Score 0	AS 0	"Avoid fluorouracil.\nNOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and* 13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient actually has gene activity score 1, for which no increased risk of severe, potentially fatal toxicity has been found with cutaneous use. These two situations can only be distinguished by determining the enzyme activity (phenotyping). This recommendation only applies if the patient has virtually no enzyme activity"	1	0	0	DPYD	fluorouracil	5039	1390
484	DPWG	PA166265421	Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers.	Intermediate Metabolizer		NO action is needed for this gene-drug interaction.	0	0	0	CYP3A4	quetiapine	4366	2788
485	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Indeterminate		No recommendation	0	0	0	CYP2C19	lansoprazole	4349	1790
486	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Indeterminate		No recommendation	0	0	0	CYP2C19	omeprazole	4349	2271
487	CPIC	PA166219103	"The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence."	Indeterminate		No recommendation	0	0	0	CYP2C19	pantoprazole	4349	2503
488	CPIC	PA166119846	"Rasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The G6PD gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence."	Normal		No reason to withhold rasburicase based on G6PD status.	0	1	0	G6PD	rasburicase	6821	2819
489	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Normal Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	1	1	SLCO1B1	fluvastatin	19487	1406
490	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Increased Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	1	1	SLCO1B1	fluvastatin	19487	1406
491	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Decreased Function		Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	0	1	1	SLCO1B1	fluvastatin	19487	1406
492	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Possible Decreased Function		Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	0	1	1	SLCO1B1	fluvastatin	19487	1406
493	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Indeterminate		No recommendation.	0	1	1	SLCO1B1	fluvastatin	19487	1406
494	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Normal Function		Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.	0	1	1	CYP2C9	fluvastatin	4351	1406
495	CPIC	PA166262341	"CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency."	Indeterminate		No recommendation.	0	1	1	CYP2C9	fluvastatin	4351	1406
496	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	CACNA1S	desflurane	2292	1004
497	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	CACNA1S	enflurane	2292	1220
498	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	CACNA1S	halothane	2292	1544
499	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	CACNA1S	isoflurane	2292	1740
500	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	CACNA1S	methoxyflurane	2292	2026
501	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	CACNA1S	sevoflurane	2292	2966
502	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	CACNA1S	succinylcholine	2292	3060
503	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	RYR1	desflurane	18364	1004
504	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	RYR1	enflurane	18364	1220
505	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	RYR1	halothane	18364	1544
506	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	RYR1	isoflurane	18364	1740
507	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	RYR1	methoxyflurane	18364	2026
508	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	RYR1	sevoflurane	18364	2966
509	CPIC	PA166180457	"The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence."	Uncertain Susceptibility		"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown [Article:28902675]."	0	0	0	RYR1	succinylcholine	18364	3060
510	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	imipramine	4352	1648
511	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	imipramine	4349	1648
512	CPIC	PA166104999	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	imipramine	4349	1648
513	CPIC	PA166176068	"The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy."	Ultrarapid Metabolizer		Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	1	0	0	CYP2D6	tamoxifen	4352	3137
514	CPIC	PA166176068	"The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy."	Normal Metabolizer	AS 1.5; AS 2	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	1	0	0	CYP2D6	tamoxifen	4352	3137
515	CPIC	PA166182603	Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.	Ultra Rapid Metabolizer		Initiate efavirenz with standard dosing (600 mg/day)	0	0	0	CYP2B6	efavirenz	4346	1186
516	CPIC	PA166182603	Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.	Rapid Metabolizer		Initiate efavirenz with standard dosing (600 mg/day)	0	0	0	CYP2B6	efavirenz	4346	1186
517	CPIC	PA166182603	Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.	Normal Metabolizer		Initiate efavirenz with standard dosing (600 mg/day)	0	0	0	CYP2B6	efavirenz	4346	1186
518	CPIC	PA166262241	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Normal Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	0	1	SLCO1B1	lovastatin	19487	1894
519	CPIC	PA166262241	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Increased Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	0	1	SLCO1B1	lovastatin	19487	1894
520	CPIC	PA166262241	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Indeterminate		No recommendation.	0	0	1	SLCO1B1	lovastatin	19487	1894
521	DPWG	PA166104957	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose."	Poor Metabolizer		"The higher plasma concentration of omeprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects."	0	0	0	CYP2C19	omeprazole	4349	2271
522	DPWG	PA166104957	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose."	Intermediate Metabolizer		"The higher plasma concentration of omeprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects."	0	0	0	CYP2C19	omeprazole	4349	2271
523	DPWG	PA166104987	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose."	Poor Metabolizer		"The higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects."	0	0	1	CYP2C19	lansoprazole	4349	1790
524	DPWG	PA166104987	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose."	Intermediate Metabolizer		"The higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects."	0	0	1	CYP2C19	lansoprazole	4349	1790
525	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	amitriptyline	4352	195
526	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	amitriptyline	4349	195
527	CPIC	PA166105006	"The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	amitriptyline	4349	195
528	DPWG	PA166182842	"Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. ""The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins"""	*1/*2	*1/*2	NO action is required for this gene-drug interaction.	0	0	0	CYP2C9	warfarin	4351	3480
529	CPIC	PA166127637	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.	Ultrarapid Metabolizer		No recommendation due to lack of evidence.	0	0	0	CYP2D6	fluvoxamine	4352	1407
530	CPIC	PA166127637	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.	Extensive Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	fluvoxamine	4352	1407
531	CPIC	PA166127637	The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	fluvoxamine	4352	1407
532	CPIC	PA166105005	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Normal Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	1	1	SLCO1B1	simvastatin	19487	2979
533	CPIC	PA166105005	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Increased Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	1	1	SLCO1B1	simvastatin	19487	2979
534	CPIC	PA166105005	"Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day."	Indeterminate		No recommendation.	0	1	1	SLCO1B1	simvastatin	19487	2979
535	DPWG	PA166104977	The Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.	Ultrarapid Metabolizer		"NO action is needed for this gene-drug interaction. The gene variation increases conversion of citalopram to a weakly active metabolite. However, there is no significant effect on the plasma concentration of citalopram, the tolerance or the response."	0	0	0	CYP2C19	citalopram	4349	819
536	DPWG	PA166104951	"Dose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count."	Intermediate Metabolizer		NO action is needed for this gene-drug interaction.	0	0	0	UGT1A1	irinotecan	22969	1725
537	DPWG	PA166104990	"Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers."	Intermediate Metabolizer		Monitor the plasma concentration.	0	0	0	CYP2C19	voriconazole	4349	3473
538	DPWG	PA166104968	"For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine."	Intermediate Metabolizer		"It is not possible to offer adequately substantiated advice for dose reduction based on the literature.\n- avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.\n- if it is not possible to avoid venlafaxine and side effects occur:\n1. reduce the dose\n2. monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.\nIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum."	1	0	0	CYP2D6	venlafaxine	4352	3423
539	DPWG	PA166104968	"For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine."	Poor Metabolizer		"It is not possible to offer adequately substantiated advice for dose reduction based on the literature.\n- avoid venlafaxine.  Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.\n- If it is not possible to avoid venlafaxine and side effects occur:\n1. reduce the dose\n2. monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine\nIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum. Furthermore, a reduced effectiveness of venlafaxine has been observed in depression patients with this gene variation."	1	0	0	CYP2D6	venlafaxine	4352	3423
540	DPWG	PA166104980	"Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration."	Intermediate Metabolizer		The gene variation has a minor effect on the sertraline plasma concentration. No effect on side effects was found.	0	0	0	CYP2C19	sertraline	4349	2963
541	DPWG	PA166104980	"Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration."	Ultrarapid Metabolizer		"The gene variation has a negligible effect on the plasma concentration of sertraline. Moreover, no significant effect on response and side effects has been found."	0	0	0	CYP2C19	sertraline	4349	2963
542	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Normal Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	celecoxib	4351	736
543	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Normal Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	flurbiprofen	4351	1400
544	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Normal Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	ibuprofen	4351	1621
545	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Normal Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	lornoxicam	4351	1890
546	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	celecoxib	4351	736
547	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	flurbiprofen	4351	1400
548	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	ibuprofen	4351	1621
549	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	lornoxicam	4351	1890
550	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Indeterminate		No recommendation.	0	0	0	CYP2C9	celecoxib	4351	736
551	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Indeterminate		No recommendation.	0	0	0	CYP2C9	flurbiprofen	4351	1400
552	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Indeterminate		No recommendation.	0	0	0	CYP2C9	ibuprofen	4351	1621
553	CPIC	PA166191841	"The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Indeterminate		No recommendation.	0	0	0	CYP2C9	lornoxicam	4351	1890
554	DPWG	PA166104976	Select an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.	Ultrarapid Metabolizer		"It is not possible to offer substantiated advice for dose adjustment based on the literature. Avoid paroxetine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include for example citalopram or sertraline."	1	0	0	CYP2D6	paroxetine	4352	2520
555	DPWG	PA166104976	Select an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.	Intermediate Metabolizer		NO action is needed for this gene-drug interaction.	0	0	0	CYP2D6	paroxetine	4352	2520
556	DPWG	PA166104976	Select an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.	Poor Metabolizer		NO action is needed for this gene-drug interaction.	0	0	0	CYP2D6	paroxetine	4352	2520
557	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Indeterminate		None	0	0	0	TPMT	azathioprine	22019	432
558	CPIC	PA166104933	Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Indeterminate		None	0	0	0	NUDT15	azathioprine	13756	432
559	CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CC	rs12979860 CC	Implications for PEG-IFN alpha and RBV: Approximately 70% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Implications for protease inhibitor combinations with PEG-IFN alpha and RBV therapy: Approximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks). Weighs in favor of using PEG-IFN alpha and RBV containing regimens.	0	0	0	IFNL3	peginterferon alfa-2a	8531	2529
560	CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CC	rs12979860 CC	Implications for PEG-IFN alpha and RBV: Approximately 70% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Implications for protease inhibitor combinations with PEG-IFN alpha and RBV therapy: Approximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks). Weighs in favor of using PEG-IFN alpha and RBV containing regimens.	0	0	0	IFNL3	peginterferon alfa-2b	8531	2530
561	CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CC	rs12979860 CC	Implications for PEG-IFN alpha and RBV: Approximately 70% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Implications for protease inhibitor combinations with PEG-IFN alpha and RBV therapy: Approximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks). Weighs in favor of using PEG-IFN alpha and RBV containing regimens.	0	0	0	IFNL3	ribavirin	8531	2851
562	CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CT or TT	rs12979860 CT; rs12979860 TT	Implications for PEG-IFN alpha and RBV: Approximately 30% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Implications for protease inhibitor combinations with PEG-IFN alpha and RBV therapy: Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN and RBV containing regimens.	0	0	0	IFNL3	peginterferon alfa-2a	8531	2529
563	CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CT or TT	rs12979860 CT; rs12979860 TT	Implications for PEG-IFN alpha and RBV: Approximately 30% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Implications for protease inhibitor combinations with PEG-IFN alpha and RBV therapy: Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN and RBV containing regimens.	0	0	0	IFNL3	peginterferon alfa-2b	8531	2530
564	CPIC	PA166110235	IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.	CT or TT	rs12979860 CT; rs12979860 TT	Implications for PEG-IFN alpha and RBV: Approximately 30% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens. Implications for protease inhibitor combinations with PEG-IFN alpha and RBV therapy: Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN and RBV containing regimens.	0	0	0	IFNL3	ribavirin	8531	2851
565	CPNDS	PA166181721	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients. The guidelines recommend that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers with an emphasis on the use of comprehensive CYP2D6 genotyping panels in guiding treatment decisions.	Poor Metabolizer		aromatase inhibitor (AI) (with ovarian suppressor in premenopausal women) or Tamoxifen (40 mg/day) when AIs are contraindicated	0	0	0	CYP2D6	tamoxifen	4352	3137
566	CPNDS	PA166181721	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients. The guidelines recommend that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers with an emphasis on the use of comprehensive CYP2D6 genotyping panels in guiding treatment decisions.	Intermediate Metabolizer		aromatase inhibitor (AI) (with ovarian suppressor in premenopausal women) or Tamoxifen (40 mg/day) when AIs are contraindicated	0	0	0	CYP2D6	tamoxifen	4352	3137
567	CPNDS	PA166181721	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients. The guidelines recommend that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers with an emphasis on the use of comprehensive CYP2D6 genotyping panels in guiding treatment decisions.	Normal Metabolizer		aromatase inhibitor (AI) (with ovarian suppressor in premenopausal women) or tamoxifen (20 mg/day) or Tamoxifen (20 mg/day) when AIs are contraindicated	0	0	0	CYP2D6	tamoxifen	4352	3137
568	CPNDS	PA166181721	The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients. The guidelines recommend that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers with an emphasis on the use of comprehensive CYP2D6 genotyping panels in guiding treatment decisions.	Ultrarapid Metabolizer		aromatase inhibitor (AI) (with ovarian suppressor in premenopausal women) or tamoxifen (20 mg/day) or Tamoxifen (20 mg/day) when AIs are contraindicated	0	0	0	CYP2D6	tamoxifen	4352	3137
569	CPIC	PA166109594	"The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction."	Normal Metabolizer		"Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration"	0	0	0	DPYD	capecitabine	5039	655
570	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Indeterminate		None	0	0	0	TPMT	thioguanine	22019	3233
571	CPIC	PA166104965	Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.	Indeterminate		None	0	0	0	NUDT15	thioguanine	13756	3233
572	DPWG	PA166104943	The Dutch Pharmacogenetics Working Group Guideline for risperidone recommends decreasing the dose for CYP2D6 poor metabolizers and using an alternative drug or titrate the dose according to the maximum dose for the active metabolite for CYP2D6 ultrarapid metabolizers.	Intermediate Metabolizer		NO action is needed for this gene-drug interaction.	0	0	0	CYP2D6	risperidone	4352	2871
573	CPIC	PA166104998	"The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	nortriptyline	4352	2240
574	DPWG	PA166104958	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose."	Poor Metabolizer		"The higher plasma concentration of pantoprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects."	0	0	0	CYP2C19	pantoprazole	4349	2503
575	DPWG	PA166104958	"For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose."	Intermediate Metabolizer		"The higher plasma concentration of pantoprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects."	0	0	0	CYP2C19	pantoprazole	4349	2503
576	DPWG	PA166104966	"For CYP2D6 poor and intermediate metabolizers, consider an alternative medication or a dose increase. For intermediate metabolizers, avoid concomitant CYP2D6 inhibitor use."	Ultrarapid Metabolizer		NO action is needed for this gene-drug interaction.	0	0	0	CYP2D6	tamoxifen	4352	3137
577	DPWG	PA166182846	"Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the *5/*6, *5/*18 or other CYP2B6 IM genotypes, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed."	*1/*5	*1/*5	NO action is required for this gene-drug interaction	0	0	0	CYP2B6	efavirenz	4346	1186
578	DPWG	PA166182846	"Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the *5/*6, *5/*18 or other CYP2B6 IM genotypes, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed."	*5/*5	*5/*5	NO action is required for this gene-drug interaction	0	0	0	CYP2B6	efavirenz	4346	1186
579	CPIC	PA166192301	"The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Normal Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	meloxicam	4351	1977
580	CPIC	PA166192301	"The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Intermediate Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	meloxicam	4351	1977
581	CPIC	PA166192301	"The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence."	Indeterminate		No recommendation.	0	0	0	CYP2C9	meloxicam	4351	1977
582	CPIC	PA166161537	"The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations."	Normal Metabolizer		Initiate therapy with recommended standard of care dosing.	0	0	0	CYP2C19	voriconazole	4349	3473
583	CPIC	PA166161537	"The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations."	Intermediate Metabolizer		Initiate therapy with recommended standard of care dosing.	0	0	0	CYP2C19	voriconazole	4349	3473
584	CPIC	PA166262261	Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.	Normal Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	0	1	SLCO1B1	pitavastatin	19487	2639
585	CPIC	PA166262261	Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.	Increased Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	0	1	SLCO1B1	pitavastatin	19487	2639
586	CPIC	PA166262261	Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.	Indeterminate		No recommendation.	0	0	1	SLCO1B1	pitavastatin	19487	2639
587	CPIC	PA166127636	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response."	Extensive Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	paroxetine	4352	2520
588	CPIC	PA166127636	"The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response."	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	paroxetine	4352	2520
589	DPWG	PA166104975	The Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.	Ultrarapid Metabolizer		"Avoid escitalopram. Antidepressants that are not metabolised or that are metabolised to a lesser extent by CYP2C19 are, for example, paroxetine or fluvoxamine."	1	0	0	CYP2C19	escitalopram	4349	1263
590	DPWG	PA166182843	"Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms."	SLCO1B1 521 CC	rs4149056 CC	"Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms."	0	1	0	SLCO1B1	atorvastatin	19487	414
591	DPWG	PA166182843	"Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms."	SLCO1B1 521 TC	rs4149056 TC	"Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms."	0	1	0	SLCO1B1	atorvastatin	19487	414
592	CPIC	PA166124619	"The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments."	Poor Metabolizer		Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments	0	0	0	CYP3A5	tacrolimus	4368	3127
593	DPWG	PA166184528	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.	Intermediate Metabolizer		"NO action is required for this gene-drug interaction. The gene variation does increase clomipramine plasma concentrations, but not clomipramine+desmethylclomipramine plasma concentrations, which determines side effects and efficacy in depression. The increase in the plasma concentration of clomipramine is favourable for the efficacy in anxiety and obsessive compulsive disorder."	0	0	0	CYP2C19	clomipramine	4349	838
594	DPWG	PA166184528	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.	Poor Metabolizer		"NO action is required for this gene-drug interaction. The gene variation increases the plasma concentration of clomipramine. However, there is insufficient evidence to substantiate an increase of the plasma concentration of clomipramine+desmethylclomipramine to such an extent that it increases the risk of side effects. The increase in the plasma concentration of clomipramine is favourable for the efficacy in anxiety and obsessive compulsive disorder."	0	0	0	CYP2C19	clomipramine	4349	838
595	CPIC	PA166219301	The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.	Indeterminate		No recommendation	0	0	0	CYP2C19	dexlansoprazole	4349	1023
596	CPIC	PA166161954	The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	ondansetron	4352	2273
597	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	clomipramine	4352	838
598	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	clomipramine	4349	838
599	CPIC	PA166105007	"Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered."	Intermediate Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2C19	clomipramine	4349	838
600	CPIC	PA166128738	"The CPIC dosing guideline recommends considering advising individuals who carry two decreased function UGT1A1 alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function UGT1A1 alleles, respectively."	Ultrarapid Metabolizer		There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result.	0	0	0	UGT1A1	atazanavir	22969	408
601	CPIC	PA166128738	"The CPIC dosing guideline recommends considering advising individuals who carry two decreased function UGT1A1 alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function UGT1A1 alleles, respectively."	Intermediate Metabolizer		"There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely"	0	0	0	UGT1A1	atazanavir	22969	408
602	DPWG	PA166104956	"Avoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers."	Ultrarapid Metabolizer		"The genetic variation results in increased conversion of clopidogrel to the active metabolite. However, this can result in both positive effects (reduction in the risk of serious cardiovascular and cerebrovascular events) and negative effects (increase in the risk of bleeding)."	0	0	0	CYP2C19	clopidogrel	4349	842
603	CPIC	PA166161955	The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).	Normal Metabolizer		Initiate therapy with recommended starting dose.	0	0	0	CYP2D6	tropisetron	4352	3349
604	DPWG	PA166104954	"CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose."	Intermediate Metabolizer		"The genetic variation increases imipramine plasma concentrations, but not imipramine+desipramine plasma concentrations, which govern effectiveness and side effects."	0	0	0	CYP2C19	imipramine	4349	1648
605	DPWG	PA166104954	"CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose."	Ultrarapid Metabolizer		"The genetic variation decreases imipramine plasma concentrations, but not imipramine+desipramine plasma concentrations, which govern effectiveness and side effects."	0	0	0	CYP2C19	imipramine	4349	1648
606	CPIC	PA166192341	The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Normal Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	tenoxicam	4351	3177
607	CPIC	PA166192341	The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Intermediate Metabolizer		"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals."	0	0	0	CYP2C9	tenoxicam	4351	3177
608	CPIC	PA166192341	The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.	Indeterminate		No recommendation.	0	0	0	CYP2C9	tenoxicam	4351	3177
609	CPIC	PA166262281	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Normal Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	0	1	SLCO1B1	pravastatin	19487	2688
610	CPIC	PA166262281	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Increased Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	0	1	SLCO1B1	pravastatin	19487	2688
611	CPIC	PA166262281	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Decreased Function		Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	0	0	1	SLCO1B1	pravastatin	19487	2688
612	CPIC	PA166262281	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Possible Decreased Function		Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	0	0	1	SLCO1B1	pravastatin	19487	2688
613	CPIC	PA166262281	Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	Indeterminate		No recommendation.	0	0	1	SLCO1B1	pravastatin	19487	2688
614	DPWG	PA166104937	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.	Ultrarapid Metabolizer		NO action is needed for this gene-drug interaction. The genetic variation decreases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is no evidence that this increases the risk of reduced effectiveness.	0	0	0	CYP2D6	aripiprazole	4352	380
615	DPWG	PA166104937	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.	Intermediate Metabolizer		NO action is needed for this gene-drug interaction.The genetic variation increases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is insufficient evidence that this increases the risk of side effects.	0	0	0	CYP2D6	aripiprazole	4352	380
616	DPWG	PA166184527	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the standard dose of brexpiprazole for patients carrying poor metabolizer alleles of CYP2D6.	Ultrarapid Metabolizer		"NO action is required for this gene-drug interaction. The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy."	0	0	0	CYP2D6	brexpiprazole	4352	578
617	DPWG	PA166184527	The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the standard dose of brexpiprazole for patients carrying poor metabolizer alleles of CYP2D6.	Intermediate Metabolizer		"NO action is required for this gene-drug interaction. There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation."	0	0	0	CYP2D6	brexpiprazole	4352	578
618	CPIC	PA166262221	Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.	Normal Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	0	1	SLCO1B1	atorvastatin	19487	414
619	CPIC	PA166262221	Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.	Increased Function		Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	0	0	1	SLCO1B1	atorvastatin	19487	414
620	CPIC	PA166262221	Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.	Indeterminate		No recommendation.	0	0	1	SLCO1B1	atorvastatin	19487	414
621	CPIC	PA166222181	There are currently no recommendations for NSAIDs dosing based on CYP2C8 genotypes.	*3	*3	The CPIC authors have evaluated therapeutic dose recommendations for ibuprofen and diclofenac dosing based on CYP2C8 genotypes. They conclude that no action is needed for this gene-drug interaction at this time.	0	0	0	CYP2C8	diclofenac	4350	1047
622	CPIC	PA166222181	There are currently no recommendations for NSAIDs dosing based on CYP2C8 genotypes.	*3	*3	The CPIC authors have evaluated therapeutic dose recommendations for ibuprofen and diclofenac dosing based on CYP2C8 genotypes. They conclude that no action is needed for this gene-drug interaction at this time.	0	0	0	CYP2C8	ibuprofen	4350	1621